Other,-916
Other,0.00001
Other,0.0001
Other,0.001
Other,0.003
Other,0.007
Other,0.014
Other,0.02
Other,0.021
Other,0.029
Other,0.32
Other,0.46
Other,0.52
Other,0.84
Other,1
Other,4
Other,4.71
Other,10.1
Other,13
Other,18.791
Other,20
Other,40
Other,42
Other,50
Other,77
Other,408
Other,700
Other,1984
Other,9398
Other,0-5Years
Other,100000Person-years
Other,1000Patients
Other,100Patients
Other,10-foldCross-validation
Other,10Mg/kg
Other,10Percecnt
Survival,10-yearBreastCancerSurvival
Other,11BreastRadiologists
Other,11Days
Hereditary,11HereditaryBreastCancerGenes
Other,120BreastCancerPatients
Other,120Patients
Other,12-15Percecnt
Other,12331Non-nsaidUsers
Other,12331Users
Other,12404Patients
Other,125DogSeraSamplesIncluding75MammaryTumourSera
Other,12EventsAmong121Patients
Other,12SampledWomen
Other,131Percecnt
Other,133BreastCancerCases
Other,133Controls
Other,13-hDailyOvernightFast
Other,13Percecnt
Other,13PercecntOfDeaths
Other,1444Women
Other,147Patients
Other,15Percecnt
Other,160Patients
Other,16PrimaryBreastCancers
Other,1722Comments
Other,17MillionPeople
Other,17MillionPeopleWorldwide
Other,17Years
Other,182Percecnt
Other,186Pathology-provenS
Other,186S
Other,193FemaleParticipants
Other,195Years
Other,1973To2014
Other,1H
Other,1Year
Other,1YearTo5Years
Other,2=
Other,2009-13
Other,2012AtBreastClinicOfPortugueseInstituteOfOncologyInPorto
Other,20BreastCancerPatients
Hazard,20PercecntIncreasedRiskOfBreastCancerAmongCurrentHormonalContraceptionUsers
Other,21Months
Other,22Deaths
Other,22Patients
Other,23Studies
Other,2-3Years
Variants,244GermlinePathogenicVariants
Variants,244GermlineVariants
Other,252Percecnt
Other,25CaseReports
Other,282Patients
Other,2921Posts
Technique,2-groupRandomizedControlTrial
Other,2IndependentCohorts
Other,30DoublingTimesNecessary
Other,30TBreastMagneticResonanceImagingExaminations
Other,32620MatchedPatientsWithoutPcos
Other,35-64Years
Other,38Months
Other,38-year-oldFemale
Other,3ClinicopathologicalFactors
Other,3GroupsBasedOnTertiarySolubleSt-2Level
Other,3-timeAssessments
Other,40Percecnt
Other,414Percecnt
Other,417Percecnt
Other,4248BreastCancerPatients
Other,428BreastCancerPatients
Other,42Patients
Other,464Percecnt
Other,476Years
Other,481Women
Other,48Years
Other,49CedmCasesCollectedFromMayoClinic
Other,49Patients
Other,4Categories
Other,4Domains
Other,505Percecnt
Other,505PercecntOfAnalyzedCases
Other,50PercecntRelapsedTissues
Other,510YearsAfterSurgery
Other,51Days
Other,51Patients
Other,535941Survivors
Other,54BreastCancerPatients
Other,56Patients
Other,57PercecntOfPatients
Other,5CmLess
Other,5-khzFrequencies
Other,5Of10Patients
Other,5-yearResultsOfPhase3Isg23-01Trial
Other,5Μl
Other,606Percecnt
Other,6084Years
Technique,60ControlPatients
Other,62Years
Other,643Percecnt
Other,643PercecntWithSignificantDifferenceBetweenWhites
Other,65Patients
Other,65-year-oldFemale
Other,67BreastCancerSamplesFrom66Patients
Other,68Percecnt
Other,6Months
Other,7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Other,70-year-oldWoman
Other,72Months
Other,731Percecnt
Other,73-yearOldWomanPresentingWithLeftBreastLumpClinicallyIndeterminate
Other,7581StageI/iiaCases
Other,768PercecntSamplesWithOverexpressionIn76Cases
Other,773Percecnt
Other,77Patients
Other,8155Patients
Other,845Percecnt
Other,84Patients
Other,876Percecnt
Other,876PercecntRespectively
Other,89FfdmCases
Other,902Percecnt
Other,905Percecnt
Other,90Percecnt
Other,90PercecntOfPatientsWithRecurrence
Other,93Percecnt
Other,952PercecntOfthePostmenopausalWomen
Other,95PercecntConfidenceIntervals
Other,976PercecntSensitivity
Other,992Percecnt
Other,992PercecntOfCases
Other,99Percecnt
Other,99PercecntAccuracyInTermsOfClassification
Other,9EuropeanCountries
Other,a
Other,aberrances
Other,aberrantDnaMethylation
Other,aberrantlyExpressed
Other,able
Other,about30Percecnt
Other,abstractDataOnTheirClinicalCharacteristics
Other,access
Other,Access
Other,accessToEarlyDiagnosis
Other,accessToReceptorAnalysesInCytosolAtDiagnosis
Other,accomplished
Other,accumulatingResults
Other,accuracy
Other,accuracyScores
Other,accurateDiagnosisOfBreastCancerSubtypes
Other,accurateMethod
Township,accurateViewOfStateOfMetastasesToAxillaryLymphNodes
Other,achieved
Other,achievedForHer2Status
Other,acid
Other,activatedComplex
Image,active
Image,activeNon-participants
Activities,activities
Resistance,activity
Cell,activityOfCellProliferationInBreastCancerCells
Other,actualIncidence
Other,Acupuncture
Susceptibility,acuteDangerToMother
Disease,AD
Other,added
Other,addition
Other,additionalAnalyses
Other,additionalIndicator
Other,additionalInformation
Technique,additionalLocalControl
Other,additionallyCorrelated
Other,additionallyRevealed
Other,adherence
Other,adherenceToEhtAmongBreastCancerPatients
Other,adherenceToRecommendationWith95PercecntConfidenceIntervals
Other,adhesionProtein-1
Other,adjacentNon-tumorousTissues
Hazard,adjustedHazardRatio
Other,adjustedProportion
Other,adjustingForPotentiallyConfoundingFactors
Other,adjuvantAnastrozole
Other,adjuvantEndocrineHormonalTherapy
Other,administered
Neoadjuvant,administrationOfNeoadjuvant
Other,adPatients
Other,adulthood
Other,advancedAnalysis
Disease,advancedBreastCancer
Other,advancedBreastCancerBearingMutations
Other,advancedBreastCancerBearingMutationsInGenesInvolvedInPi3k/ark/mtorSignalingPathway
Other,advancedDiagnosticImaging
Other,advancedStage
Other,advances
Other,advancesInBreastCancerDiagnosis
Advantage,advantage
Technique,advantageOfHigh-throughputLuminexTechnique
Other,advantages
Other,adverseEventsExceptDegreeI-iiBleeding
Other,affected
Other,after6Months'TherapySignificantlyHigherIn3rdTertiaryGroup
Other,age
Other,age-basedScreeningPrograms
Other,ageGroups
Other,age-matchedSystematicRandom-samplingMethod
Other,agents
Other,ageOfTreatmentMethods
Other,agonistic/antagonisticBiocharacter
Other,agreement
Other,aim
Other,aimed
Disease,AION
Mechanism,alarm
Other,alarmingLevelGlobally
Other,alcoholConsumption
Other,alexnetModels
Other,algorithm
Other,alive
Other,all
Other,allBreastCancerPatients
City,almatyCity
Phenotype,alongsideRoutineMethodEmployedOnTexture
Other,alreadyWell-established
Other,alsoAssessed
Other,alsoAssessedByQrt-pcr
Other,alsoShaped
Other,alsoUsed
Other,alteredInHumanBreastCarcinoma
Other,alternativeContrast-enhancedScreeningTools
Other,alternativeMeans
Other,alternativeOption
Other,alternativeToFrozenSections
Other,AMD3100
Disease,amenorrhea
Other,amongThemNewlyIdentifiedInStudy
Other,amount
Other,amplifications
Other,an
Other,analysed
Other,analyses
Other,analysis
Other,Analysis
Other,analysisInvestigate
Care,analysisMayAid
Other,analysisOfLncrnaExpressionProfiles
Other,analyzed
Other,analyzedBeforeAnd
Other,analyzedRetrospectively
Care,analyzedtheOperationTime
Other,analyzing
Chemical,anastrozole
Other,andfemales
Other,Anemia
Other,annexinVStaining
Other,annualMammographyAssociatedWithEchography
Radiotherapy,anthracyclineChemotherapyAgents
Other,Anthracyclines
Other,anti-apoptoticEffectsOfEstradiol
Other,antibodies
Other,antibody-anchoredMagneticBeads
Strategy,antibody-basedStrategy
Other,antibodyDrugConjugates
Membrane,antibodyPanel
Other,anticipated
Hazard,anticipatedOutcome
Susceptibility,antigenIdentification
Other,anti-oncogenicRegulationOfMir-34s
Other,anti-ronMonoclonalAntibodyZt/g4-drugMonomethylAuristatinEConjugate
Resistance,anti-tumorActivity
Disease,anxiety
Other,apoptosis
Image,appearance
Other,Applications
Other,applied
Other,appliedTo70PatientsWithUnilateralRl
Other,approaches
Other,appropriateDiagnosisOfBreastCancer
Other,appropriateInterpretation
Other,appropriateSequencing
Other,approximately75PercecntOfBreastCancers
Other,aptamerMf3
Other,archivedFormalin-fixedParaffin-embeddedTissue
Other,area
Other,areaOfResidence
Other,areas
Other,areaUnderReceiverOperatingCharacteristicCurve
Other,areUsed
Other,arms
Other,aromataseInhibitor-inducedBoneLoss
Other,article
Other,asInCaseShouldAlwaysKeptInMindSpeciallyInHighVolumeCenters
Other,aspects
Cytology,aspirationCytology
Other,aspirinUse
Hazard,asResultAreUsed
Other,assay
Other,assessed
Other,assessedinclusionCriteriaForEnrolment
Other,assessedPreoperatively
Other,assessment
Exposure,assessmentOfImpactOfAdvancesInDiagnosisOfPatientsWithBreastCancer
Other,assessments
Other,associated
Hazard,associatedWithBreastCancerRisk
Other,associatedWithPfsAlthoughAtExtent
Mechanism,association
Vulnerability,associationBetweenNsaidsExposureInFemalePatientsWithAd
Mechanism,associationBetweenPost-diagnosisLow-doseAspirinUse
Mechanism,associationBetweenPost-diagnosisUseOfLow-doseAspirin
Mechanism,associationBetweenPreviousCervicalCancerScreeningInBreastCancerScreening
Mechanism,associationBetweenRace/colorInWomenWithBreastCancer
Mechanism,associationBetweenTumorUptakeInInvasiveDuctalCarcinoma
Mechanism,associationOfPcdh10Methylation
Mechanism,associationOfToll-likeReceptor6WithBreastCancerInSaudiArabianWomen
Other,Associations
Other,associations
Other,associationsOfFactorsWithLocoregionalAtDiagnosis
Susceptibility,associationsOfPhysicalActivityInGlobalHealthInBreastCancerSurvivors
Mechanism,associationStudy
Other,asymptomaticWomen
Other,at25HPost-injectionGreaterInTumorBedThanInKidneyRespectively
Other,atEndOfFollow-upClassifiedRegardingTheirAdherenceToRecommendationsForCancerPrevention
Membrane,atrophiedVaginalMucosa
Other,attempted
Care,attention
Atypia,atypia
Other,AUC
Other,australianSynchrotron
Other,authors
Autoantibodies,autoantibodies
Disease,autoimmuneDiseases
Other,automatedAnalysisOfClinicallyRelevantHistopathologicFeature
Susceptibility,automaticIntraoperativeIdentificationOfBreastCancerMargins
Other,autonomyOfPatients
Other,autopsyStudies
Other,available
Other,availableContrastAgents
Other,average
Other,averageOf425±496Ctcs/2Ml
Sites,averageOfFiveInvolvedSites
Other,avoidance
Other,awareness
Other,axillaryClearance
Other,axillaryDissection
Other,axillaryLymphNode
Other,axillaryLymphNodeOfBreastCancerPatients
Other,axillarySurgery
Other,AYAs
Exposure,backgroundParenchymalEnhancement
Other,backgroundTrastuzumab
Other,baGroup
Chemical,baicalin
Chemical,Baicalin
Other,balb/cNudeMiceBearing
Susceptibility,barcodeMode
Other,bareCapillaries
Mechanism,barrierFunction
Other,Barshi
Other,base
Other,based
Other,baselineBpeLevels
Other,baselineSolubleSt-2Level
Other,baselineSt-2Level
Other,basis
Other,bayesianNetworkMeta-analysis
Other,Belgium
Other,benchmarkMethod
Other,benign
Other,benignBreastLesions
Symptom,bestAvailableEvidence
Other,bestChancesOfCure
Other,bestStandardTreatmentRegimenAvailable
Other,better
Other,betterAccessToAtertiaryCancerCenter
Other,betterDiagnosticAccuracyThanFfdm
Other,betterOs
Other,betterOutcomes
Advantage,betterOutcomeWithGoodNegativePredictiveValue
Other,betterPrognosis
Other,betterResults
Other,betterUnderstanding
Other,betterUnderstandingOfRisksAssociatedWithM
Other,bevacizumab-relatedCardiotoxicity
Other,bilateralBreastLumps
Other,bilateralMastectomies
Other,bilateralSalpingo-oophorectomy
Other,bilateralTotalMastectomies
Other,binaryLogisticRegressionModels
Other,binding
Vitro,bindingToBreastCancerCellsInVitro
Other,biocharacter
Other,bioimpedanceAnalysis
Other,biologicalSubtypes
Other,biomarker
Other,biomarkers
Other,Biomarkers
Other,bio-metal-organicFrameworkCoated
Biopsy,biopsy
Other,blackWomen
Other,blood
Other,bloodSamples
Other,BMI
Mechanism,body
Mechanism,bodyMassIndex
Mechanism,bodyWeight
Other,boneDensity
Disease,boneLoss
Other,bone-modulatingAgents
Other,BPE
Other,bpeLevels
Other,brainMetastases
Disease,brainMetastasis
Gene,BRCA1
Gene,BRCA1/2
Other,brca-associatedCancers
Other,BRCAs
Other,breast
Disease,breastCancer
Other,breastCancerAged
Other,breastCancerCases
Cell,breastCancerCellInvasion
Other,breastCancerCells
Other,breastCancerClassification
Other,breastCancerConfinedWithinMammaryDuctsSurrounded
Technique,breastCancerControl
Technique,breastCancerControlEfforts
Technique,breastCancerControlEffortsForIdentification
Other,breastCancerDetectionMethod
Disease,breastCancerDiagnosis
Other,breastCancerGenes
Cytology,breastCancerGenetics
Cytology,breastCancerGeneticsInKenya
Other,breastCancerGrading
Other,breastCancerIncidence
Other,breastCancerMcf-7
Other,breastCancerMetastasis
Other,breastCancerModels
Other,breastCancerMolecularSubtypes
Other,breastCancerPatients
Other,breastCancerPatientsSerum
Other,breastCancerPatientsWith1-2PositiveSlnspatientsWithBreastCancer
Survival,breastCancerPatientsWithParticularReferenceToOverallSurvivalAndrecurrenceFreeSurvivalAmongBreastCancerPatients
Other,breastCancerRelapse
Hazard,breastCancerRisk
Disease,breastCancers
Other,breastCancerScreening
Other,breastCancerScreeningProgramme
Survival,breastCancer-specific10-yearSurvival
Disease,breastCancerStaging
Other,breastCancerStudies
Other,breastCancerSubtypesa
Other,breastCancerTherapy
Other,breastCancerTissueMicroarrayWithAccessToReceptorAnalyses
Other,breastCancerTissues
Disease,breastCancerWisconsin
Other,breastCancerYoungerThan45Years
Disease,breastCarcinoma
Other,breastConservation
Other,breastExamination
Other,breastImagingModality
Other,breastMetastases
Other,breastMetastasis
Neuromas,breastNeuromas
Other,breastScreening
Survival,breastSurvival
Disease,breastTumor
Other,breastTumorMicroenvironment
Other,breastTumorProgression
Cell,breastTumorProgressionIncludingTumorCellGrowth
Other,broadcasted
Other,broadDifferentialDiagnosis
Other,broadUseToPatients
Other,bromideAssay
Other,bronchoalveolarCarcinomaUnrelatedToKnownMetastaticBreastCancer
Other,bt549Cells
Other,bulkyHighlyTechnical
Other,byDevelopmentOfHybridomaTechnologyHaveProducedInManyLaboratories
Other,byWhichObservedInNondestructiveWayThroughThermalAnalysis
Other,C
Other,C1
Other,ca15-3ByCmia
Other,ca15-3Detection
Other,caDetection
Other,calculated
Other,caloricRestriction
Cell,canCategorized
Cell,canCategorizedIntoSubtypesOfLuminalA
Disease,cancer
Other,cancerAssociatedFibroblasts
Care,cancerCareCenter
Care,cancerCareNetwork
Care,cancerCareSystems
Other,cancerCells
Technique,cancerControlPlanning
Other,cancerCounseling
Other,cancerDeathAmongWomenWorldwide
Other,cancerDiagnosis
Other,cancerFibroblasts
Disease,cancerGenomeAtlas
Other,cancerMolecularDiagnosis
Disease,cancer-relatedDeath
Disease,cancer-relateddeaths
Other,cancer-relatedDeathsAmongWomen
Cell,cancer-relatedEventsIncludingTumorCellMigration
Other,cancerResearch
Hazard,cancerRiskPerception
Cell,cancerStemCellHypothesis
Susceptibility,cancerSusceptibilityGenes
Other,cancerTreatment
Cell,canClassified
Cell,canConsidered
Cell,canDiagnosed
Cell,canDifficult
Cell,canEasilyExtended
Cell,canEffectivelyTreatedByEndocrineTherapy
Cell,canExtended
Cell,canHeavilyInfluenced
Cell,canImportant
Cell,canImportantToDiagnosis
Cell,canIncluded
Cell,canIncludedInDifferentialDiagnosisOfMasses
Other,canines
Other,canineTumours
Cell,canOnlyDiagnosedOnPresentationOfSymptoms
Cell,canStarted
Cell,canStartedAtVeryEarlyStage
Cell,canTherapeuticTargetForNextGenerationOfSerms
Cell,canUsed
Other,capabilities
Cell,capacitance
Susceptibility,capacity
Other,capecitabineRegimenAsThird-lineTreatmentForAdvancedTriple-negativeBreastCancer
Other,capillaries
Other,carbohydrateRestriction
Other,carbonDioxideLaserTechnology
Disease,carcinogenesis
Disease,carcinoma
Disease,cardiacInjury
Other,cardiacTroponins
Hazard,cardiotoxicRisk
Care,care
Care,careProvider
Other,carrier
Other,case
Hereditary,case-controlAssociationStudyForVariantsInCodingRegionsOf11HereditaryBreastCancerGenesIn7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Image,caseOf68-year-oldCaucasianFemaleWithFamilyHistoryOfCancer
Other,caseRecords
Other,Cases
Other,cases
Other,casesWithoutMetastasisOnDiagnosticImaging
Risk,cause
Other,causes
Other,ccsCoverage
Other,CEDM
Cell,cell
Other,Cell
Cell,cellCycleArrestFollowedByMassiveCellDeath
Cell,cellCycleRegulators
Cell,cellInvasion
Symptom,cell-killingEffect
Symptom,cell-killingEffectInTriple-negativeSubtypeMda-mb-231Cells
Cell,CellLines
Cell,cellMigration
Cell,cellProliferation
Other,Cells
Other,cells
Other,centralDenmarkRegion
Other,CGI
Other,challenge
Other,challengingProblem
Other,chances
Other,changes
Susceptibility,changesInHealthBehavioursAfterBreastCancerDiagnosis
Susceptibility,changesToIntimateIssuesIncludingSexualHealth
Other,chapter
Other,characteristics
Other,characteristicsInsideTumors
Other,characterization
Other,characterized
Radiotherapy,chemotherapy
Radiotherapy,chemotherapyGroups
Radiotherapy,chemotherapyHormonalTreatment
Radiotherapy,chemotherapyRecommendations
Radiotherapy,chemotherapyRegimens
Resistance,chemotherapyResistance
Scans,chestCtScans
Other,Chi
Other,childbearingReasonsIncluding
Other,childHealth
Other,China
Other,chineseExpertGroup
Other,chinesePublic
Other,chlorambucilPlatinum
Resistance,choiceOfChemotherapyInBrca-associatedCancers
Other,Cholecystectomy
Disease,chorea
Disease,choreiformMovements
Other,chosen
Other,chronic
Other,chronicDebilitatingLifelongComplication
Other,circRNAs
Other,circulatingSolubleRankl
Other,circulatingTumorCells
Other,clarify
Other,classified
Other,classifiers
Other,CLB-Pt-CLB
Other,clb-pt-clbProdrug
Other,clearcellPlatform
Symptom,clearEvidenceForbenefitsOfTanUsageInBreastCancerClassification
Other,clinicalBreastCancerTrials
Other,clinicalBreastExamination
Other,clinicalBreastExaminationCoupledAsPrimaryTool
Care,clinicalCare
Other,clinicalCharacteristics
Care,clinicalCharacteristicsOfCareOfBreastCancerPatients
Other,clinicalDepression
Other,clinicalFeasibilityOfCtcIsolation
Other,clinicalOutcomesDiffer
Other,clinicalPicture
Other,clinicalPractice
Other,clinicalRecords
Other,clinicalSetting
Other,clinicalSettingOfPreviouslyVagueDiagnosisInImaging
Other,clinicalVariablesAmongDifferentGroups
Other,clinicalVisits
Other,clinicians
Other,clinico-epidemiologicalFeaturesOfBreastCancer
Other,clinicopathologicalCriteria
Other,clinico-pathologicalFeaturesOfMetastases
Hazard,clinico-pathologicalRiskFactors
Phenotype,closedLoopStructure
Other,closelyAssociated
Other,CMIA
Other,CNN
Other,cnvData
Other,CNVs
Other,cnvsOfDifferentCancers
Other,coding
Other,Co-existence
Other,cohortStudy
Other,collapsing
Other,collected
Susceptibility,collectedFromElectronicHealthRecord
Other,collectedSignatures
Disease,collisionTumor
Other,collisionTumorWithBreastCancerMetastasis
Survival,colonyFormation
Other,combination
Other,combinedAnalysis
Membrane,combinedPanel
Other,common
Image,commonAdultCancers
Other,commonCancer
Other,commonCancerTypes
Risk,commonCause
Risk,commonCauseOfMorbidity
Other,commonComplaint
Susceptibility,commonEndocrineDisorder
Other,commonMalignancyWorldwide
Other,commonMalignantDisease
Other,commonMedications
Other,commonPlatformForStakeholdersIncludingPolicymakers
Comorbidities,comorbiditiesThanSPatients
Other,compared
Other,comparedBetween2GroupstheApatinib
Other,comparedBetweenMetastaticSlns
Other,comparedBetweenPremenopausalGroupsBetweenPcrGroups
Other,comparedToThoseWithPregestationalBreastCancer
Other,comparison
Other,comparisonCohort
Other,comparisonOfPredictedIncidenceOfBreastCancerWithActualIncidenceInPopulation-basedStudies
Other,comparisons
Other,Comparisons
Survival,comparisons10-yearSurvival
Other,comparisonToCa15-3
Other,complaint
Other,complementaryApproaches
Other,completionOfReproductivePlans
Other,complex
Other,complexConsulting
Other,complexDueToPotentialFoetalRisksInSettingOfMaternalTreatment
Surgeries,complexSurgeries
Other,complexTreatmentAlgorithms
Other,complication
Other,components
Other,comprehensiveResearchData
Other,comprehensiveSearch
Other,Computer
Other,concentrations
Other,concentrationsOfVegf-aInComparisonToCa15-3InBreastCancer
Care,concernForExistenceOfCancerCellsInGrafts
Other,concerns
Other,conclusionsWomen
Other,conditions
Other,conducted
Other,confirmed
Other,confirmedUnilateralHer2-positiveBreastCancer
Resistance,conflict
Care,conflictBetweenCareOfMother
Other,conjugatedEquineEstrogen
Other,connected
Other,consensus
Other,consensus-based
Vulnerability,consensusOnAssociationBetweenExposureToDdt
Other,consequencesForSurvival/relapse
Other,consequentlyHaveDeveloped
Other,conservativeTreatment
Toxicity,considerableNumber
Other,considered
Other,consistent
Other,consistentMass-spectralData
Other,consultations
Other,context
Other,contextOfBreastCancer
Other,contexts
Contraception,contraceptionUse
Mechanism,contraceptiveUse
Other,contrast
Other,contrastAfterInjection
Other,contrastAgents
Other,contribution
Technique,control
Technique,controlGroup
Other,controls
Technique,controlTrial
Other,controversial
Other,conventionalBafifty-fivePatientsUndergoingViaMabaForPtmc
Other,conventionalTreatmentProcesses
Other,conventionalX-rayMammography
Other,convolutionalNeuralNetworks
Other,copyright
Radiotherapy,correctionMethod
Other,correlated
Correlation,correlation
Correlation,correlationCoefficient
Correlation,correlationCoefficientOnMetabricTrainingSet
Other,correlationsBetweenOdds
Other,correspondingCohort
Image,correspondingHistologyImage
Costs,costs
Other,couldConsidered
Other,couldDetected
Other,couldDetectedByMammographyBySelf-detection
Other,couldDetectedEarly
Other,couldIndependentPrognosticBiomarkerForMPatients'Outcomes
Other,couldPotentialBiomarker
Other,counseling
Township,country
Resistance,course
Other,coverage
Other,coverageRates
Hazard,coxHazardRegressionAnalysis
Hazard,coxHazardRegressionModels
Exposure,coxModel
Hazard,coxProportionalHazardModel
Hazard,coxProportionalHazardRegressionModels
Other,cpgIslands
Other,craniotomy
Other,created
Other,critical
Other,criticalRole
Other,criticalScientificBase
Other,criticalScientificBaseForPrecisionMedicineInBreastCancer
Other,cross-sectionalCategories
Other,cross-sectionalStudy
Other,cross-validation
Other,crucial
Exposure,crucialImpactOnDevelopmentOfBreastCancer
Other,crucialRole
Other,cruciferousVegetables
Other,Cryopreservation
Other,cscMarkers
Other,cssBenefit
Other,CTC
Other,ctcCounts
Other,ctcIsolationTechniques
Other,CTCs
Other,ctcsFromPeripheralBlood
Other,CTIBL
Other,cTn
Other,ctnLevels
Other,currentAnalysis
Other,currentCancerResearch
Other,currentFollow-up
Other,currentlyInsufficient
Other,currentMeans
Other,currentResults
Other,currentUsersOfLongerDuration
Other,currentUtilizedHistopathologicBiomarkers
Other,cutaneousManifestationsOfBreastCancer
Other,cutoff
Other,cutoffValues
Other,CXCR4
Other,cylindricalGeometries
Other,cytohistologicalComparisons
Other,cytologicalExamination
Cytology,cytology
Disease,cytotoxicity
Toxicity,cytotoxicityOfFreeDoxMolecules
Other,D538G
Susceptibility,danger
Other,Data
Other,data
Other,dataAnalytics
Other,dataOfN=
Other,date
Other,DAU
Disease,DCIS
Other,dcisDiagnosis
Other,dcisWithMicroinvasion
Other,DCR
Chemical,DDE
Chemical,DDT
Vulnerability,ddtExposure
Other,DDTs
Other,ddtSprays
Resistance,dealingWithEndocrineResistanceInPatientsWithBreastCancer
Disease,death
Other,deathInWomenWorldwide
Other,debated
Other,decades
Other,decrease
Other,decreased
Other,decreasedBpe
Other,decreasedExpression
Other,decreasedGrowth
Hazard,decreasedRisk
Hazard,decreasedRiskOfBreastCancerInFemaleAdPatients
Other,decreases
Other,decreasesInMortalityRates
Other,deep-CNN
Other,deepLearning
Other,defectStudies
Other,defined
Subtype,definedSubtype
Other,delay
Other,Delays
Other,delaysinTreatment
Other,delivery
Other,Demographics
Other,demonstrate
Other,denosumabInjection
Other,denseBreasts
Other,dependent
Other,dependentOnRigorousPathologicEvaluationOnAdministrationOfTreatmentDictatedByTumorBiology
Other,depletion
Other,Depletion
Other,deregulatedMirnas
Other,described
Other,description
Other,descriptive
Other,descriptive-analyticCross-sectionalType160FemalePatientsWasselected
Other,descriptiveStudy
Other,designed
Gene,DESI-MSI
Other,desirable
Other,despiteTheirRarityShouldConsidered
Other,detailedRoles
Other,detected
Other,detectedByImmunohistochemistryInApproximately70PercecntOfInvasiveBreastCancers
Other,detectedThroughScreeningThroughSigns
Other,detection
Other,detectionMethod
Other,detectionofBreastCancer
Other,detectionOfBreastCancerInWomen
Other,detectionOfCancer
Other,detectionOfMicrocalcificationInMammograms
Other,detectionRate
Other,detectionRateOfMutationsHigherThanThatDescribedInLiterature
Other,determinationOfUnderlyingBiologyWithinTumors
Other,determine
Other,determined
Other,determining
Other,developed
Other,development
Other,Development
Other,developmentOfBrainCancers
Other,developmentOfBreastCancer
Other,developmentOfEffectiveDrugsForTreatmentOfHormone-dependentBreastCancer
Other,developmentOfGraphicallyTailoredScreeningTool
Other,developmentOfLymphedema
Other,developmentOfNewDrugs
Other,developmentOfPolicies
Other,developmentOfSubsequentLung/bronchusCancer
Other,diagnosed
Other,diagnoses
Other,diagnosis
Other,diagnosisAccuracy
Other,diagnosisOfAcuteCoronarySyndromes
Other,diagnosisOfBreastCancer
Other,diagnosisOfCancer
Other,diagnosisOfEstrogenReceptor
Other,diagnosisOfGallbladderMetastasis
Other,diagnosisOfPatientsWithBreastCancer
Signature,diagnosisOfResponseToTreatment
Other,diagnosisOfSulinicalPrimaryCarcinomas
Other,diagnosticAccuracy
Other,diagnosticEvaluation
Other,diagnosticRole
Other,diagnosticUncertainty
Other,dictionaryLearning
Other,diet
Other,difference
Other,differenceBetweenClearcellPlatformsForIsolatingCtcs
Other,differenceBetweenDifferentBreastCancerSubtypes
Other,different
Other,differentBreastCancerMolecularSubtypes
Other,differentContrastAgent
Other,differentDetectionRates
Other,differentDetectionRatesInBreastCancerPatients
Other,differentFunctionRegions
Hereditary,differentGeneticProfile
Other,differentHistologicalAspects
Other,differentialDiagnoses
Other,differentialDiagnosis
Other,differentialDiagnosisInPatientsWithHistoryOfBreastSurgery
Other,differentiallyExpressedInBreastCancerCells
Other,differentials
Other,differentiation
Other,differentiationBetweenBreastCancerInVariousSubtypesOfBreastCancer
Long-term,differentLong-termSurvival
Other,differentmethodsOfSelf-treatment
Other,differentPatientRaces
Other,differentPhenotypes
Other,differentPhotosensitizerForPhotodynamicTherapy
Other,differentPrognosis
Protocols,differentProtocols
Other,differentStages
Other,differentStudies
Subtype,differentSubtype
Chemical,diindolylmethane
Susceptibility,diminishedOncospheroid-formingCapacityOfBreastCancerCells
Other,directEffects
Other,directTargetGene
Other,disadvantages
Exposure,discovery
Other,discrete-timePartiallyObservableMarkovDecisionProcess
Other,discussed
Other,Disease
Other,disease
Other,diseaseDefinedByTumor
Other,diseases
Other,Diseases
Other,disposition
Other,dissection
Other,dissectionOfLymphNodes
Other,disseminatedDisease
Other,distinct
Hereditary,distinctiveGeneticModifications
Other,distributions
Other,diverse
Other,diverseBiologicalProcesses
Other,divided
Other,dnaMethylation
Other,dnaMethylationDifferencesBetweenTumorBreastTissue
Other,documented
Other,documentedAsImportantTumor-promotingAgentForSeveralHumanCarcinomasIncludingBreastCancer
Other,dominantArms
Other,doses
Other,double-maintenanceTherapy
Other,doublingTimeOfOccult
Other,downregulated
Other,down-regulated
Other,down-regulatedInTissues
Other,doxUptakeByCs/bio-mof
Other,DPV
Other,dramaticallyIncreasedAmount
Other,drastic
Other,drawbacks
Other,driven
Other,drugBinding
Other,drugDeliveryStrategies
Susceptibility,dryness
Other,DSCAM-AS1
Other,dscam-as1Expression
Assays,dual-luciferaseReporterAssays
Other,dual-phaseContrast
Disease,ductalCarcinoma
Other,ductalCarcinoma
Other,duringAgeAssociatedWithIncreaseOf8MoreFemaleBreastCancerCasesPer100000DuringAge50-54
Other,dynamicContrast
Disease,dyspareunia
Other,dysregulation
Hazard,earlyBiomarkersOfBreastCancerRisk
Other,earlyBreastCancer
Other,earlyBreastCancerDetectionSystems
Other,earlyBreastCancerSurgery
Other,earlyCancerDiagnosis
Other,earlyDiagnosis
Other,earlyStage
Other,earlyStageDiagnosisOfTumors
Other,ecchymosis
Other,eConcentration
Other,edition
Symptom,effect
Other,effective
Other,effectiveDiagnosisOfBreastCancer
Other,effectiveness
Other,effectivenessOfDifferentNpatsOnQolInPatientsWithBreastCancer
Other,effectivenessOfNationalScreeningProgrammes
Symptom,effectOfBaicalinInBreastCancer
Symptom,effectOfDdtSpraysOnBreastCancerIncidenceRate
Symptom,effectOfDscam-as1
Other,effects
Other,effectsOfPcosOnRisksOfGynecologicCancer
Other,effectsOfTreatment
Other,efficientSignaturesForClinicalDiagnosis
Other,eighthEdition
Other,elderlyPatients
Other,electiveCholecystectomyForSymptomaticCholelithiasis
Other,electricalDouble-layerCapacitors
Disease,elevatedLesion
Other,ELISA
Other,elusive
Other,elusiveToTargetedTherapies-theTriple-negativeBreastCancer
Other,embeddingIntoReproducingKernelHilbertSpace
Susceptibility,emergingPublicHealthProblemInLowCountries
Other,emergingTechnology
Other,EMH
Other,emphasis
Other,empiricalTreatmentsBasedOnClinical-pathologicalCharacteristicsToUseOfTargetedApproaches
Other,employed
Resistance,endocrineResistance
Resistance,endocrineTherapyResistance
Image,energyImage
Other,enforcedExpression
Other,englishLiterature
Other,enhancedPossibility
Image,enhancementOfImage
Other,enhancerRegions
Other,enrolled
Other,epidemiologicalFeatures
Other,epigeneticAberrations
Exposure,equivalentPerformance
Signalling,eralphaSignalling
Other,eralphaTranscription
Gene,ERBB2
Other,erCscs
Other,er-dependentTranscriptionalActivationViaTransactivationFunction1
Other,erEvaluation
Other,erImmunohistochemistry
Other,er-positive/humanEpidermalGrowthFactorReceptorType2-negativeBreastCancers
Other,er-positiveBreastCancer
Gene,ESR1
Other,esr1-activatingMutations
Other,esr1Alterations
Other,esr1Mutations
Other,esr1SomaticAlterations
Other,essential
Other,essentialRole
Other,established
Other,estimated
Other,estimates
Chemical,estrogen
Chemical,Estrogen
Other,estrogen-aloneArmOfWhi
Vulnerability,estrogenicExposure
Other,estrogenReceptor
Other,estrogenReceptor-alpha
Other,estrogen-receptorAmongOtherMarkers
Chemical,estrogens
Other,ET
Other,europeanCountries
Other,evaluated
Vivo,evaluatedInVivo
Other,evaluation
Other,evenLessFrequentComplication
Other,evenMorePersonalizedFollow-upSchedules
Radiotherapy,evenSeveralChemotherapySessions
Hazard,eventHybridizationOfMirna-21Biomarker
Other,events
Other,eventualKnowledge
Symptom,evidence
Other,evidence-basedRecommendations
Other,evidencedByIncreaseInContrastAfterInjection
Symptom,evidenceForbenefits
Other,evolve
Other,evolveTowardLessSurgery
Other,examination
Other,examined
Exposure,excellentPerformance
Exposure,excellentPerformanceInFieldOfMedicalImagesDiagnosis
Technique,excellentRegionalControl
Other,excision
Other,excision/lumpectomy
Other,exercise
Other,existence
Symptom,existingEvidenceOnPersonalGoal-settingAmongWomenWithBreastCancerDiagnosis
Other,exon32OfMammalianTargetOfRapamycin
Other,expected
Correlation,expectedInverseCorrelation
Correlation,expectedInverseCorrelationOfSerumDdtsWithBmi
Other,experience
Other,experiences
Other,experimentalStudyOfCryo-stabilityOfCancerCells
Other,experts
Other,explored
Vulnerability,exposure
Other,expressed
Other,expressedSeparately
Other,expression
Other,expressionInBreastCancer
Other,expressionLevel
Other,expressionLevels
Other,expressionOf6CirculatingMirnasInOperablePatients
Other,expressionOfCxcChemokineReceptor-4
Other,expressionOfMir-511InBreastCancer
Other,expressionOfRrm2
Other,expressionProfileOfNek6In133BreastCancerSpecimens
Care,extensiveAttentionOfResearchers
Other,extensiveExploration
Other,extensiveMolecular
Other,extramedullaryHaematopoiesis
Other,extremeLearningMachineClassification
Other,fabricated
Other,facilitatingRole
Other,factor
Other,factor-1Scores
Factor,factorAnalysis
Other,factors
Other,Factors
Other,factorsRelatedToPresenceOfMetastaticDiseaseAtDiagnosis
Other,Familiarity
Other,familyHistoryOfDisease
Exposure,familyImpact
Other,familySupport
Disease,fanconiAnemia
Other,faSignalingNetwork
Other,fastDayBefore
Other,fastingBlood
Other,fastRate
Other,f-boxProtein22
Other,Fbxo22
Other,fbxo22-dependentManner
Care,fearOfPartnerLoss
Other,feasible
Other,feasibleCtcIsolationTechniques
Quantification,feasibleInProperlySelectedCasesWithAsymptomaticNeuromasAfterAccurateTissueSampling
Other,features
Other,featuresFromImages
Image,february2012InNargisDuttMemorialCancerHospital
Other,female
Other,femalePatient
Other,femalePatients
Other,femalePatientsWithAd
Other,femaleSibling
Other,fewerInstancesOfSpreadToLungs
Other,fewPercentOfWomen
Other,fewStudies
Other,FFDM
Disease,fibroadenoma
Other,fibroblasts
Other,fibroblastsAdjacent
Other,field
Other,fieldOfBreastCancerDetection
Other,fieldOfMedicalImagesDiagnosis
Other,figures
Other,filipinoWomen
Exposure,finalMultipleRegressionModel
Other,finding
Other,findings
Other,Findings
Cytology,fine-needleAspirationCytology
Other,firmlyPlaceWithRecentTrendsTowardDecreasedRatesOfRe-excision
Other,firstDataOnPre-diagnosisConcentrationsOfSrankl
Other,firstDiagnosis
Other,firstFiveFacebookOpenBreastCancerGroupsInYear2016
Other,first-lineTreatment
Other,firstOrganisedRound
Other,firstPatientsWithPathologicallyTumor-freeNodes
Other,firstSteps
Symptom,firstSymptom
Other,firstTime
Other,firstTimeIn1984
Other,fisherAnalysis
Other,fisherDiscriminantAnalysis
Other,fitted
Other,five
Other,fiveGroups
Other,fiveYearRfsrate
Other,flankingCgi
Survival,flowCytometry
Survival,flowRate
Other,fluorescenceImaging
Vivo,fluorescenceImagingExVivo
Other,focus
Other,followed
Other,followedFromDateOfFirstDiagnosisOfAdToEndOf2013
Other,following
Other,Follow-up
Other,follow-up
Other,follow-upSchemes
Other,foodRecommendations
Other,forefront
Other,forefrontOfResearch
Other,formed
Other,formedByCo-encapsulationOfNear-infraredFluorophoreInPegylatedMicelles
Other,formulation
Other,formulationOfEffectiveManagementPlanForAt-riskWomen
Other,forRace/colorVariableEstimatedWithAdjustmentForStatus
Other,forThoseWithNormalLvef93Percecnt
Other,forWomenWithBreastCancerMayMoreFeasible
Other,found
Other,foundBetweenMolecularSubtypesWithHer2
Other,foundInPcosCohortThanInComparisonCohort
Other,fourTypesOfBreastCancer
Other,FOXC1
Other,foxc1-knockdownBt549Cells
Other,framework
Other,frequentCancer
Other,frequentLargeSingleGiantCellsWithNucleiLocatedPredominantlyWithinSupsularSinuses
Other,frequentMutations
Other,FT
Other,function
Other,functionalAssessments
Other,functions
Other,furtherDevelopment
Other,furthermoreAssociated
Other,furthermoreMoreLikely
Other,furthermoreSignificantlyMoreLikely
Other,furtherResearch
Other,furtherStudies
Other,furtherTissue
Other,furtherUnderstanding
Other,fused
Other,fusionProteinsWithHaloTag
Other,future
Other,futureClinicalStudies
Other,futureInterventions
Gene,FXYD3
Other,fxyd3Amplification
Other,G
Cell,g1/s-phaseCellCycleArrest
Other,geneExpressionLevel
Other,geneExpressionUpregulationInBreastCancer
Other,generalBreastCancerPopulation
Susceptibility,generalHealth
Other,generallyReserved
Other,generalPopulation
Other,generalRadiologistAboutSystemicDiseases
Other,genes
Other,genesInvolved
Hereditary,geneticChanges
Hereditary,geneticMutation
Other,geometries
Other,given
Susceptibility,globalHealth
Other,glut1Expression
Glycosylation,glycosylation
Glycosylation,glycosylationOfMembraneTypeMr
Other,goal
Other,goal-setting
Other,gonadotropin
Advantage,good
Advantage,goodCorrelationBetweenErAnalysedWithCytAtDiagnosisAnalysedWithIhcInArchivedFfpeTissueFromSameTumour
Advantage,goodDiagnosticAbility
Advantage,goodDiagnosticPerformance
Symptom,goodQualityEvidence
Advantage,goodTolerabilitytheApatinib
Other,grade
Other,grafts
Exposure,greatClinicalImpactForTumorDiagnosis
Other,greater
Susceptibility,greaterthanorequalto10PercecntDecline
Oxidation,greaterthanorequalto10PercecntReductionInLvef
Oxidation,greaterthanorequaltoReduction
Other,greatPotentialInDiagnosisTherapyOfCancers
Resistance,greatPotentialOfClinicalApplication
Other,greatProgress
Other,greatPromise
Other,group
Other,group1
Other,group2
Other,groups
Other,growth
Other,growthOfFbxo22-depletedEr-positiveBreastCancers
Other,GTPase
Other,gtpaseInBreastCancerCells
Other,guidedImagery
Guidelines,guidelines
Other,gynaecologicalMetastases
Other,HADS
Other,haMoietyForPdt
Other,handheldProbeCapable
Advantage,handicap
Other,harmfulorHarmlessTissues
Susceptibility,harmToHealthAmongRuralWomenWithIncrementalCost-effectivenessRatio
Other,hasAlreadyAssociatedWithDifferentCancersNon-hodgkin'sLymphoma
Other,hasApplied
Other,hasAssociated
Other,hasFocused
Other,hasFocusedOnTumourCellsPrimarily
Other,hasFound
Other,hasInconsistent
Other,hasMade
Other,hasMadeInMolecularSubtypingOfBreastCancer
Other,hasProposed
Other,hasPut
Other,hasPutOnIntrinsicSubtypingBasedInPresenceOfClassicalImmunohistochemistry
Other,hasRecentlyProposedAsCrucialRegulatorOfTriple-negativeBreastCancer
Other,hasReported
Other,hasSuggested
Other,hasUsed
Other,hasWidelyUsed
Other,haveAssociated
Susceptibility,haveAssociatedWithNippleAreolaComplexInvolvementInPatientsWithBreastCancer
Other,haveBackbone
Other,haveBackboneOfSuchEnormousStridesOfAu
Other,haveCenterstage
Other,haveClarified
Other,haveDescribed
Signature,haveDescribedInResponseToNeoadjuvantChemotherapyParticularlyInAssociationWithHerceptinTreatment
Other,haveDeveloped
Other,haveDiscovered
Other,haveObserved
Other,haveProducedInLaboratories
Other,haveReported
Other,haveReportedForFirstTimeInCaninesInStudy
Other,haveReportedInOnly003-06PercecntOfBreastCancers
Other,haveReportedMainlyAfterMastectomy
Other,haveStudiedInTermsOfCrosstalkBetweenEstrogenReceptorAlpha
Other,haveUsed
Other,haveValidatedByClinicalStudiesInCardiotoxicityDiagnosisInPatientsTreatedWithHighDosesOfAnthracyclinesAloneInCombinationMainlyWithTrastuzumab
Hazard,hazardRates
Hazard,hazardRatiosWith95PercecntConfidenceIntervals
Susceptibility,health
Susceptibility,healthBehaviours
Care,healthcareCost
Care,healthCareSector
Care,healthcareUtilization
Susceptibility,healthCenters
Susceptibility,healthExpectancyOfItspopulation
Other,healthInitiative
Disease,heartFailure
Symptom,heavySymptomBurden
Other,henceMainlyBased
Other,henceMajorResearchGoal
Gene,HER2
Other,her2/hrTripleNegativeTnmStages
Other,her2Overexpressing
Other,her2-positiveA
Disease,her2-positiveBreastCancer
Other,her2-positiveInvasiveDuctalCarcinoma
Other,her2Status
Other,Herceptin
Hereditary,hereditaryCausesOfChorea
Disease,hereditaryDisease
Heterogeneity,heterogeneity
Other,heterogeneous
Other,heterogeneousCancerInFemalePatientsWorldwide
Disease,heterogeneousDisease
Image,heterogeneousDiseaseInItsHistologicAppearance
Other,heterogeneousPopulationsOfCellsWithHierarchicalOrganizationDrivenByCancerStemCells
Other,high
Other,highAmountOfDox
Correlation,highCorrelation
Other,highCoverage
Other,highDetectionRateOfSentinelLymphNodeComparableWithRiMethod
Other,higher
Other,higherProportion
Other,higherProportionOfPatientsWithLymphedema
Other,higher-qualityImaging
Other,higherRatesOfMisdiagnosisForBreastCancer
Other,higherResolution
Other,higherRisks
Other,higherRisksOfTreatmentDelays
Other,highestIncidenceAmongMalignanciesDiagnosedInWomen
Exposure,highestPerformance
Hazard,highestRisk
Other,highestSe
Other,highestSeInTotalGroup
Other,highExpression
Other,highGlut1Expression
Other,highIndex
Hazard,highlyDiverseGroupOfMalignantNeoplasiaWithPoorOutcome
Other,highlyEffective
Other,highlyExpressed
Other,highlyPenetrantGenes
Other,highlySensitiveNano-biosensor
Other,highMortalityRateForFemales
Other,high-resolutionImages
Other,highSensitivity
Other,highVolumeAcademicCenters
Other,histologicalExamination
Other,histologicGradeInBreastCancer
Cytology,histology
Other,histoneModifications
Other,histopathologicalExamination
Other,histopathologicallyProvedBreastTumors
Other,histopathologicalreports
Other,history
Other,historyOfBreastCancer
Other,historyOfBreast-conservingSurgery
Other,historyPhysicalExamFindings
Contraception,hormonalContraceptionUse
Other,hormone-dependentPositiveBreastCancer
Other,hormoneReceptor-positiveTumors
Other,hospitalCohort
Other,hospitalFromJanuary2016ToFebruary2017
Other,howeverElusive
City,howeverGreaterforPatientsTreatedInAlmatyCity
Other,howeverHaveClarified
Other,howeverKnown
Other,howeverMoreDrastic
Other,howeverMuchLower
Other,howeverNon-ideal
Other,howeverSwitched
Other,howeverUnderutilized
Other,howeverWidelyUnderstood
Gene,HR
Disease,HT
Other,hugeVolumes
Species,human
Other,humanBiofluid
Mechanism,humanBody
Other,humanChorionicGonadotropin
Other,humanEpidermalGrowthFactorReceptor2ReceptorStatus
Other,humanErrors
Other,humanLife
Other,hundreds
Other,hybridCultures
Symptom,hyperglycemia
Other,hypomethylated
Hypomethylation,hypomethylation
Sites,hypomethylationSites
Other,hypothesis
Other,ICER
Other,icgFluorescenceMethod
Other,identifiablePcrResults
Other,Identification
Susceptibility,identification
Hereditary,identificationOfDistinctiveGeneticModificationsInDifferentBreastCancerMolecularSubtypes
Susceptibility,identificationOfPredictiveBiomarkersForSelectionOfOptimalTreatment
Other,identified
Other,illiterate
Image,image
Image,imageQuality
Other,imagery
Other,images
Image,imageSegmentation
Other,imaging
Other,imagingIndexes
Other,imagingInvestigations
Other,imagingModalities
Technique,imagingTechnique
Other,immediateUnmetNeed
Other,immediateUnmetNeedInClinicalPractice
Other,immune-mediatedCancer-associatedDisorders
Other,immunocaptureOfMarker
Immunohistochemical,immunohistochemicalAnalysis
Other,immunohistochemicalDetectionOfErPerformedInRoutineClinicalPractice
Other,immunohistochemicalTests
Other,Immunohistochemistry
Exposure,impact
Other,impairedBaselineCardiacFunctionExperience
Other,impededApoptosis
Other,imperative
Other,importance
Other,importanceOfNondestructiveTestingInDefectStudies
Other,importanceOfProactivelyAddressingFertility
Other,important
Resistance,importantApplicationProspects
Other,importantComponent
Other,importantContributors
Advantage,importantCopingResource
Other,importantForDiagnosis
Other,importantInsightsIntoDiagnosisOfPatientsWithDisease
Other,importantlyCouldPotentialDiagnosticBiomarkerInEthnicPopulation
Other,importantPotential
Other,importantProblem
Other,importantRole
Other,importantTumor-promotingCells
Other,improved
Other,improvedCancerTreatment
Other,improvedDetection
Other,improvedDiagnosis
Other,improvedQualityOfLife
Other,improvedUnderstanding
Susceptibility,improvement
Susceptibility,improvementInClassificationOfMalignantLesions
Other,inAdditionFurtherConfirmedInEarlyStage
Other,inAssay
Other,inBelgiumMostFrequentWomen'sCancerAccountingForTo353PercecntOfCases
Other,inBreastTumorsKnownAsBreastCscs
Other,inCanadaOfferedInOrganizedPrograms
Other,inCaseReportTypicalOfAdvance
Other,inCaseSecondaryToProximalBronchialObstruction
Other,inception-v3Cnn
Other,incidence
Other,incidenceAmongMalignancies
Other,incidenceFactors
Other,incidenceFactorsOfSubsequentLung/bronchusPrimaries
Other,incidenceRates
Other,incidentalFinding
Other,inclined
Other,included
Other,included.When
Other,includedInStudy
Other,including
Other,inclusion
Other,incompleteExcisionOfMalignantTissues
Other,inConclusionDownregulatedInBreastCancer
Hereditary,inConclusionMajorHereditaryBreastCancerGenesIrrespectiveOfAgeAtDiagnosisInJapaneseWomen
Other,inConclusionPathogenicFeatureInPrimarySamples
Other,inConclusionStillNecessaryForAdoptionOfCtnAsRoutineClinicalBiomarkerInPatientsWithBreastCancer
Other,inConclusionStronglyAssociatedWithNonparticipationInS
Other,inconsistentResults
Other,Increase
Other,increase
Other,increased
Other,increasedMalignantPotential
Hazard,increasedRisk
Hazard,increasedRiskOfEndometrialCancer
Hazard,increasedRiskOfMortality/relapse
Hazard,increasedRiskOfTherapy-relatedMorbidity
Hazard,increasedRiskWithUseOfLevonorgestrelIntrauterineSystem-bothOfPotentiallyImportantFindings
Other,increasedRonExpression
Other,increases
Toxicity,increaseWithNumberOfSprays
Toxicity,increasingNumber
Other,independent
Other,independentlyAssociated
Other,independentPrognosticFactor
Other,independentPrognosticFactorForDfsOfEarlyStageBreastCancer
Other,independentPrognosticPredictor
Other,indicative
Other,indicator
Other,indicatorOfNacEffectiveness
Other,indispensable
Hazard,individualRiskOfRecurrence
Other,Individuals
Other,individuals
Other,induction
Other,inexpensive
Technique,inexpensiveTechnique
Other,infiltrationSimilar
Other,infiltrativeLesion
Other,inflammatoryDiseases
Disease,inflammatoryTumour
Other,influenceOfSleepQualityOnPmInPatientsTreatedWithHt
Other,influences
Other,inFluorescenceImaging
Other,Information
Other,information
Other,infraredFluorescentDye
Vitro,infraredFluorescentImagingInTripleNegativeInVitro
Hereditary,inheritableBi-objectiveCombinatorialGeneticAlgorithm
Other,inhibited
Other,inhibition
Other,inHumanBreastCancerHasReported
Other,initialPresentationOfInvasiveBreastCancer
Other,initialTreatmentAfterWhich
Other,initiationOfBreastMalignancy
Other,initiationOfPromptTherapy
Other,injury
Long-term,inLongTermHasFound
Signature,inMarch2014BroadcastedAsPart
Other,inMultivariateModelsRelatedToPerformanceStatus
Other,inNearFutureContribute
Other,inPaperUsed
Cell,inPresentStudyConductedBetweenMcf-7Tamoxifen-resistantLcc2CellLines
Other,inPresentStudyPerformedFor9Features
Other,inPrimaryBreastCancerTumorsExpressedDuringNeoplasticTransformation
Other,insight
Other,insights
Other,inStudyDevelopedByCell-selex
Other,inStudyDevelopedForHighlyEfficientIsolationOfCtcsFromBreastCancerPatients
Cell,inStudyFusedWithMouseMyelomaCellLineSp2/0InPresence
Other,insufficient
Other,intelligentTechniques
Other,intensive
Advantage,interest
Other,interference
Other,interimStageInProgressionFromDcisToInvasiveBreastCancer
Guidelines,internationalGuidelines
Other,interplay
Other,interpretation
Signature,interval
Signature,intervalBetweenDiagnosis
Care,intervention
Care,interventionArm
Other,interview
Other,intopreGroups
Other,inTotalDiagnosedUnderAgeOf50
Other,inTotalMatchedToCasesOnBirthYear
Other,intracellularLevel
Survival,intralaboratoryValidationSet
Cytology,intraoperativeScrapeCytology
Heterogeneity,intratumoralHeterogeneityOfKindOfTumor
Other,intravenousAdministrationOfOsteopontin-750Probe
Parameters,intravoxelIncoherentMotionParameters
Other,invasion
Disease,invasiveBreastCancer
Disease,invasiveBreastCarcinoma
Other,invasiveCarcinomaBreast
Other,invasiveDiseaseretrospectiveAnalysisOf219Cases
Disease,invasiveDuctalCarcinoma
Cytology,invasiveLobularHistology
Other,inverselyCorrelated
Other,investigated
Other,investigatedOnly
Investigation,Investigation
Other,involved
Susceptibility,involvement
Strategy,inWorkSynthesizedAsSystemForDeliveryOfDoxorubicinInTreatmentOfBreastCancer
Other,iraqiWomenWhencomparedToWesternWorld
Other,irregularHyperintenseLesion
Other,irregularHyperintenseLesionInT2InLeftParietalRegion
Other,Isolation
Other,Israel
Other,isReplaced
Radiotherapy,isReplacedWithRadiotherapyInSituations
Other,isSentinelLymphNodesMetastasesTo1-2Nodes
Other,issues
Other,issuesOfExistingContrastAgents
Other,issuesRelatedToTherapeuticSequencingInLocalTherapyOfBreastCancer
Other,It
Other,it
Other,itInvolvesInManyCrucialMetabolicProcesses
Other,its
Exposure,itsDiagnosticPerformance
Other,itsExpression
Other,itsExpressionLevel
Image,itsHistologicAppearance
Survival,itsMinimalSilverIonReleaseProfiles
Exposure,itsPerformance
Other,itsPoorPrognosis
Other,itsRole
Other,iU22
Parameters,ivimParameters
Other,jak-statPathway
Other,Japan
Other,Japanese
Other,kaplanMeierCurves
Other,kaplan-meierCurves
Other,kaplan-meierRegressionMethods
Other,Kazakhstan
Other,KDM4B
Other,Kenya
Other,kernelApproach
Signature,key
Sites,keyHypomethylationSites
Other,keys
Other,keysToSuccessfulChestWallResectionForLocallyRecurrentBreastCancerAfterMastectomy
Other,Ki67
Other,kind
Other,kinds
Other,knockdown
Other,knowledge
Other,knowledgeOfM
Other,knowledgeSummaries
Other,known
Other,knownHeterogeneousDisease
Other,label-freeDetection
Other,large
Other,largeBreastCancerTissueMicroarray
Other,largeCells
Other,largelyConsistent
Other,large-scaleStudies
Other,lastFollow-upTime
Other,late-stage
Other,late-stageCancerDiagnosis
Risk,leadingCauseOfDeathAmongGynecologicNeoplasias
Other,learning
Other,leastAbsoluteShrinkage
Other,leftParietalRegion
Other,lesion
Other,lessLikely
Other,lessVisits
Other,leucocytes
Other,level
Other,levels
Other,levelsOfEralphaProtein
Other,life
Signature,lifestyleModification
Other,life-threatening
Other,ligand-bindingDomainAllInBreastCancerSamplesFromPatientsPreviouslyTreatedWithEndocrineTherapy
Other,likelihood
Other,likelihoodOfDetectionOfMicrometastases
Other,likely
Paraneoplastic,likelyParaneoplastic
Other,limitations
Other,limitedLiterature
Exposure,limitedPerformanceForWomenWithDenseBreasts
Other,linearRegression
Other,linerRegressionAnalysis
Other,linked
Other,lipidProfiles
Other,lisbonRegion
Other,literature
Other,little
Survival,littleSurvivalVariance
Other,lobularCarcinoma
Other,localExcision/lumpectomy
Other,localizedDescription
Other,localizedDescriptionOfBreastCancer
Other,locallyAdvancedBreastCancer
Other,localRecurrence
Other,localTherapy
Other,localTherapyOfBreastCancer
Other,locoregionalDiseaseOfUnspecifiedLocation
Radiotherapy,locoregionalRadiotherapy
Other,logisticregressions
Other,longerPeriods
Other,longerPfs
RNAs,longNoncodingRnas
Long-term,long-termEstimates
Other,long-termUse
Other,loss
Other,lossOf020Quality-adjustedLifeYears
Other,lowClassificationAccuracies
Other,lowCountries
Other,lowCtnLevels
Other,lowDiagnosticSensitivityForWomenWithDenseBreasts
Other,lower
Hazard,lowerCumulativeHazardRates
Other,lowerInEasternThanNorthern/centralEurope
Other,lowLevel
Hazard,lowRiskLesions
Other,luciferaseReporterAssay
Other,luminalB-likePatients
Other,lung/bronchusMalignancies
Disease,lungCancer
Other,lungCancerInHuman
Other,lungChanges
Other,lungMetastasesFromBreastCancerPresented
Disease,LVEF
Other,LVI
Other,lymphaticInvasion
Other,lymphedemaPatients
Other,lymphedemaseventyPatients
Other,lymphNodeMetastasisInPatientsWithBreastCancer
Other,lymphocytes
Other,M
Other,m
Other,mab1e3
Other,mabaSurgery
Other,macrophages
Other,macrophage-targetedTreatmentStrategies
Other,made
Other,magneticResonanceImaging
Other,main
Other,mainChallenge
Other,mainContribution
Other,mainlyEurope
Other,mainlyPostmenopausalWomen
Other,mainMeasures
Other,mainObjective
Other,maintainedBreastCancerDatabase
Care,maintenanceOfErCancerStemCells
Other,major
Other,majorCscMarkersDescribedInInvasiveBreastCancer
Other,majority
Disease,maleBreastCancer
Other,malePatients
Other,malign
Disease,malignancies
Disease,malignancy
Other,malignant
Disease,malignantPleuralEffusion
Other,malignantProgressionOfBreastCancer
Other,mammaryMetastasisFromCarcinomaOfOvarianOrigin
Other,mammograms
Other,Mammographic
Other,mammographicBreastCancerScreening
Other,mammographicImages
Other,Mammography
Other,Management
Other,management
Other,managementOfTumour-relatedSymptoms
Other,manifold
Other,manufactured
Other,manyBreastCancerPatients
Other,manyComputerVisionApplications
Other,manyFeatures
Other,manyPatients
Other,manyResearchers
Other,markedlyUp-regulated
Other,markerBands
Other,markers
Other,mass
Other,massInPosteriorFossaOfBrain
Other,massiveCircrnas
Other,massMedia
Other,massProduction
Other,massSpectrometry
Other,mastectomiedPatients
Other,mastectomies
Other,mastectomizedWomen
Other,mastectomy
Other,matched
Other,matchedHealthyTissues
Other,material
Other,materialDetection
Correlation,matthewsCorrelationCoefficientOf8038Percecnt
Other,mayDistinctEntity
Advantage,mayGoodChoiceForUnilateralPtmc
Other,mayIndicativeOfBenignLesion
Other,mayNecessary
Other,mayUsed
Other,mayUsedForTumourShrinkagePriorToSurgery
Other,MCC
Other,mda-mb-231Cells
Other,mean
Other,means
Other,meanTime
Other,meanwhileBetterThanInCapecitabineGroup
Other,measurements
Other,measures
Mechanism,mechanism
Other,mechanisms
Other,Mechanisms
Other,medianAge
Other,medianDiagnosisAge
Other,medianFollow-upOf48Years
Other,medianFollow-upOf9·
Signature,medianInterval
Survival,medianProgression-freeSurvival
Other,medianTime
Other,medicalDiagnosisOfBreastCancer
Other,medicalHistory
Other,medicalStatus
Other,medications
Other,megakaryocyteMarker
Other,megakaryocytes
Chemical,melatonin
Membrane,membraneTypeMannoseReceptor
Membrane,membraneTypeMr
Image,memorialSloanKettering-integratedMutationProfilingOfActionableCancerTargets
Other,menopausalHormoneTherapy
Survival,metabricTrainingSet
Other,metastasectomy
Disease,metastases
Disease,metastasis
Disease,Metastasis
Other,metastasisFromLobularBreastCarcinoma
Disease,metastaticBreastCancer
Disease,metastaticDisease
Other,metastaticDisease
Other,method
Other,methods
Other,methodsDesign
Other,methylation
Other,methylationStatus
Other,methylationStatusOfPcdh10InBreastCancerTissues
Other,MethyLight
Other,microarrayAnalysis
Other,microfluidicChips
Other,microfluidicPlatform
Other,microfluidicsBiomarkerDetection
Disease,micrometastasis
Gene,microRNA-22
Other,microrna-22ExpressionLevels
Other,microRNAs
Other,MicroRNAs
Other,microscopicExamination
Other,microscopicImages
Other,microscopicTestingOfHematoxylin
Strategy,mightPromisingTherapeuticStrategyForHormone-therapyRefractoryEr
Other,minimal
Other,minimalRisksToNormalCells
Toxicity,minimumToxicityToNormalCells
Other,mir-193b-3pBinding
Other,mir-193b-3pBindingTo3UntranslatedRegionOfMorc4
Other,mir-193b-3pIdentifiedAsRegulator
Other,miR-204-5p
Other,miR-34s
Other,miR-511
Other,mir-511Expression
Other,mir-511Overexpression
Other,mirnaExpressionProfiles
Other,miRNAs
Other,misdiagnosis
Other,missed
Other,mistaken
Other,mistakenDiagnosisOfMalignancy
Other,mixedMethodsDesign
Exposure,model
Other,modeled
Other,modified
Other,molecularAnalyses
Other,molecularBasis
Other,molecularChanges
Other,molecularDiagnosisMethodMake
Other,molecularPathwaysInvolvedInPathogenesisOfProliferation
Regulatory,molecularRegulatoryNetworks
Other,monteCarloFeatureFeatureMethod
Other,monteCarloFeatureSelection-basedFeatureSelection-basedComputationalMethod
Susceptibility,mood
Susceptibility,moodOfLife
Gene,MORC4
Other,morc4Silencing
Other,morcFamilyCw-typeZincFinger4Overexpression
Other,moreAdvancedStages
Other,moreAdvancedStagingAtDiagnosisInWomen
Other,moreAggressiveBiologicalNatureThanPureDcis
Comorbidities,moreComorbiditiesThanSPatients
Other,moreDesirable
Other,moreDirectional
Other,moreEasilyHypomethylated
Other,moreEffectiveTreatmentOfLungCancers
Other,moreInclined
Other,moreInformationAboutFurtherStratificationOfBreastCancerSubtypes
Other,moreIntensiveFollow-up
Other,moreLikely
Cell,moreoverPerformedOnMcf-7CellLineInPresenceOfCs/bio-mofCarrier
Other,moreoverPoor
Other,moreoverRemarkablyIncreased
Other,moreoverStronglyRecommended
Other,moreRecentlyHaveDeveloped
Other,moreRecommended
Other,moreRefinedStratificationThanAnatomicStageAlone
Susceptibility,moreResearchLight
Other,moreSatisfiedWithTheirCosmeticResultsThanThose
Other,moreTargetedAdjuvantTreatments
Other,morphologicalDifferentials
Parameters,morphologicParameters
Other,mortality
Other,mortalityRate
Other,mortalityRates
Other,MortalityRates
Other,most
Image,mostCommonAdultCancersInKenya
Other,mostCommonAgentsUsedInBreastCancerTreatment
Other,mostCommonCancer
Other,mostCommonCancerInWomen
Other,mostCommonCancerOfAdolescentsAgedAccountingFor56PercecntOfInvasiveBreastCancerInWomen
Other,mostCommonMalignantTumor
Other,mostCommonNeoplasms
Other,mostCountries
Other,mostEffectiveTechniqueused
Other,mostEuropeanCountries
Other,mostFrequentCancerInWomenTreatedWithHormonalTherapy
Other,mostFrequentlyDiagnosedCancer
Other,mostFrequentlyOccurringCancer
Other,mostFrequentMalignancy
Other,mostInvasiveDisease
Paraneoplastic,mostLikelyParaneoplastic
Other,mostNondestructiveTests
Other,mostPatients
Other,mostPervasiveTypeOfCancerAmongWomen
Other,mostPowerfulTool
Other,mostPretermBirth
Other,mostPrevalentMalignancyAmongWomenAroundWorldAreDiagnosedYear
Other,mostPrevalentMalignancyDiagnosedInPregnancy
Other,mostPrevalentType
Risk,mostProminentCause
Other,mostRelevantKind
Other,mostStigmatization
Other,mostWomen
Other,MP
Other,mPatients
Other,MRI
Other,mriImaging
Other,mrnaExpressionLevelOfPcdh10
Other,MSOT
Other,msotImaging
Other,mStage
Other,mtorInhibitorEverolimus
Other,muchFocus
Other,multicenterStudy
Quantification,multidimensionalScaling
Other,multidisciplinaryAssessment
Care,multidisciplinaryCare
Other,multigenePanels-with
Strategy,multimodalityTreatmentStrategy
Other,multimodalTherapy
Other,multipleBiological
Hereditary,multipleGeneticAberrances
Other,multipleSolicitations
Other,multiplexAssay
Autoantibodies,multiplexedAssayForDetectionOfAutoantibodiesInCanineTumours
Hazard,multiresolutionResult
Other,multi-stimuli-responsiveTheranosticNanoplatform
Other,multivariate
Hazard,multivariateCoxProportionalHazardRegressionAnalysis
Other,multivariateModelsAdjustedForIncome
Image,multiyearCollaborationLedByUnionForInternationalCancerControl
Other,murineMonoclonalAntibodies
Other,mustAddressed
Hereditary,mustAddressedDuringCancerGeneticCounselingConsultations
Other,mustIndividualized
Care,mustIndividualizedWithEmphasisOnOptimalCareOfMother
Other,mutationalStatusBesidesFamilyHistory
Other,mutationEvents
Other,mutationRatio
Other,Mutations
Other,mutations
Other,myeloperoxidase
Other,NAC
Other,nano-biosensor
Other,nanocarrier
Other,nano-genosensor
Other,nanoplatform
Other,nationwideRegistries
Other,nature
Other,navigationSurgery
Gene,NCAM1
Other,necessary
Other,necessity
Other,need
Other,needed
Care,neededAcrossCareContinuumEspeciallyInLow-resourceSettings
Other,needForAnalysisOfMetastaticTissuesAtRecurrence
Other,needForAwarenessOfMimicsOfBoneMetastasis
Radiotherapy,needForNodalRadiotherapyInSpecificSituations
Other,needsInPrevention
Other,negativeEffects
Other,negativelyCorrelatedWithLvef
Other,negativeMargins
Other,neglected
Other,Nek6
Other,nek6Expression
Radiotherapy,neoadjuvantChemotherapy
Radiotherapy,neoadjuvantChemotherapyGroups
Radiotherapy,neoadjuvantChemotherapyWithHerceptin
Neoadjuvant,neoadjuvantSetting
Neoadjuvant,neoadjuvantTreatment
Other,neonatal
Other,neonatalOfRetrospectiveCohortOfPregnantWomenWith
Disease,neoplasms
Image,netherlandsCancerRegistryOf37230PatientsWithEarlyBreastCancer
Resistance,netvizzApplication
Other,networkOutput
Other,networks
Other,neuralNetworkClassifier
Other,neuroma
Other,neutralEffects
Other,neutrophil-to-lymphocyteRatio
Other,newBilateralIntrapulmonaryNodules
Other,newDesignDouble-layerCapacitors
Other,newerDrugDeliveryStrategies
Other,newOpportunitiesForDevelopmentOfNovelTherapeuticStrategies
Other,news
Other,newSpecificMarkers
Other,newTreatmentRegimens
Other,nextMade
Other,nf-krab-inducedIncreasedExpressionOfCcnd1
Susceptibility,nippleAreolaComplexInvolvement
Susceptibility,nippleInvolvement
Strategy,nirFluorescenceImagingSystem
Other,nirProbe
Other,NLR
Other,NMA
Other,nodalMegakaryocytes
Exposure,nomogram
Other,non-coverage
Other,nondestructiveTesting
Other,nondestructiveTests
Other,non-ideal
Other,noninvasive
Other,noninvasiveImaging
Technique,noninvasiveImagingTechniqueForBreastCancerDiagnosis
Other,Non-linearity
Other,non-nsaidUsers
Other,nonparticipation
Other,non-sentinelLymphNode
Hazard,non-standardLessPromptTreatmentsIrrespectiveOfComorbiditiesWithIncreasedRiskOfMortality/relapse
Other,non-standardPromptTreatments
Other,normalCardiacFunction
Other,normalDucts
Other,normalSamples
Other,normalTissues
Other,notablyDesigned
Other,noted
Susceptibility,noticeableDrugLoadingCapacity
Other,novelInsightsIntoPotentialMechanismsAssociatedWithBreastCancerPathogenesis
Other,novelMethod
Other,novelNavigationSurgery
Other,novelNear-infraredNirFluorescentProbe
Technique,novelPowerfulTechnique
Symptom,novelStrategiesForDiagnosisOfBreastCancerWithHyperglycemia
Other,novelTargetedTherapeuticOptions
Targets,novelTherapeuticTargetsFor
Other,novelty
Other,nowAlsoWidelyUsed
Vulnerability,nsaidExposure
Other,NSAIDs
Vulnerability,nsaidsExposure
Other,nsaidUsers
Other,nslnMetastasis
Other,n-typeVoltage-gatedV-gCalciumChannelBindingAntibodies
Atypia,nuclearAtypia
Species,nudeMice
Toxicity,number
Toxicity,numberVariants
Other,numerousGene-expression-basedPrognosticSignatures
Disease,obesity
Other,Obesity
Other,objective
Signature,objectiveResponseRate
Other,objectives
Other,obscure
Other,observationalStudies
Other,observations
Other,observed
Other,obstetrician
Other,obstetricians
Other,obtained
Other,obtainedFeatures
Survival,obtainedFrom66FemalePatientsWithMAtDifferentTimeIntervalsForEvaluationOfCtcsByFlowCytometry
Other,obtainedFromPatientsWithBreastCancer
Other,occultBreastTumors
Other,occurrence
Other,occurrenceOfBreastCarcinoma
Other,occurring
Other,occurringCancers
Other,odds
Other,oedema
Other,oestrogenReceptorAlpha
Other,oestrogenReceptorCofactors
Other,oestrogenReceptorPositiveIn58PercecntOfCasesPositiveIn62Percecnt
Other,of121Patients
Other,offered
Other,oftenDebated
Other,oftenHypomethylated
Other,oftenRelated
Symptom,oftenWellScrutinisedByPathologistsForEvidenceOfMetastaticCarcinomaAsImportantPrognosticParameterInStandardSetting
Other,old
Other,olderWomen
Chemical,omega3FattyAcids
Acids,omegaFattyAcids
Other,omission
Other,oncogenes
Other,oncogenesEsr1
Other,oneExtraVisit
Other,oneMutation
Other,oneRandomlyAssignedToAxillaryDissection
Other,oneRegion
Other,oneRegionAnother
Other,oneScreeningProgramme
Other,onEsophagogastroduodenoscopyIdentifiedInAntrum
Subtype,oneSpecificSubtype
Other,one-waySensitivityAnalyses
Other,ongoingTrials
Other,only1ulOfSerumSample
Other,only20Percecnt
Other,only35Cases
Neuromas,only35CasesOfTraumaticBreastNeuromas
Other,only44Percecnt
Other,onlySubgroupWithProgesteroneReceptor
Other,onlyWomen
Other,Ontario
Other,OP
Biopsy,openBiopsyOfNodularityAttachedToPectoralMuscleFascia
Other,operablePatients
Other,opportunities
Other,opticalAbsorptions
Other,opticalCoherenceTomographyImages
Other,optimalCut-offValue
Other,optimalCutoffValues
Other,optimalTherapeuticTargetForPatientWithAdvancedBreastCancer
Other,options
Other,OR
Other,organotropic
Other,ORR
Disease,OS
Advantage,osAdvantage
Other,osteopontin-750Accumulation
Other,osteopontin-basedProbe
Other,osteopontinPeptide
Other,otherAgeGroups
Other,otherData
Other,otherDietaryRecommendations
Other,otherInotherTertiaryCentres
Other,otherSignificantConcerns
Sites,otherSites
Other,otherSubtypesOfBreastCancer
Other,ourAim
Other,ourBreastCancerPatients
Other,ourExperience
Radiotherapy,ourExperienceOfHigh-doseRadiotherapy
Technique,ourFacility
Other,ourFindings
Other,ourLiteratureReview
Other,ourPatient
Other,ourPreviousWorkRegardingToPropertiesOfPluronicsWithDifferentPhotosensitizerForPhotodynamicTherapy
Other,ourResults
Other,ourStudy
Other,ourTheoreticalAnalysis
Hazard,outcome
Hazard,outcomeInEr-positive/humanEpidermalGrowthFactorReceptorType2-negativeBreastCancersWithHighHazardRatiosIndependentlyOfOtherMarkers
Hazard,outcomeInLymphedemaPatients
Other,outcomes
Other,outcomesOfEstrogenReceptorPositive
Other,outliers
Other,ovarianCancer
Other,overallLowOfSixCirculatingMirnas
Survival,overallMedianSurvival
Other,overallMediumSecondTumor-freeTime
Disease,overallSurvival
Other,overexpressed
Other,overexpression
Overexpression,Overexpression
Other,overnight
Other,over-represented
Other,overview
Oxidation,oxidationPeakCurrent
Other,P
Other,p
Other,painless
Other,painlessLumpInBreastAccountingFor688PercecntOfPatients
Other,pairedTumor
Other,pairedUntreatedPrimaryTumor
Gene,PALB2
Radiotherapy,palliativeChemotherapy
Membrane,panel
Resistance,panelOf25GenesInvolvedInMechanismsOfTargetedTreatmentResistanceIn16PrimaryBreastCancersDevelopedDuringTreatment
Cell,panelOfCellLinesWithDifferentPhenotypes
Cell,panelOfMonoclonalAntibodiesAgainstNewlyEstablishedCellLine
Other,paper
Parameters,parameters
Other,parameterUncertainty
Paraneoplastic,paraneoplasticAntibodyPanel
Disease,paraneoplasticNeurologicSyndromes
Other,parpInhibitors
Signature,partialPathologicalResponseWithLargeAreasOfTumourRegression
Species,participants
Other,participantsWithBreastCancer
Other,particular
Other,particularEmphasisQuantifying
Other,pathogenesisOfBreastCancer
Other,pathogenic
Variants,pathogenicVariants
Variants,pathogenicVariantsInBrca1/2
Other,pathologicallyTumor-freeNodes
Other,pathologicalResults
Other,pathologicalSpecimen
Other,pathologicEvaluation
Other,pathologistAnnotation
Other,pathologists'Awareness
Other,pathologyForFurtherFollow-up
Other,pathway
Species,patient
Other,patientEducationIdentification/reportingOfSideEffects
Other,Patients
Species,patients
Species,Patients
Other,patientsByTrastuzumab-pretreatment
Survival,patientSelectionForNon-pcosReferenceCohort
Other,patient'sMedicalHistory
Other,patients'MedicalRecords
Other,patientsOnAromataseInhibitors
Other,patients'Prognosis
Other,patients'Self-monitoring
Other,patient'sTumorBurden
Other,patientsWithBreastCancer
Other,patientsWithBreastCancerReceivingWithAnthracyclines
Other,patientsWithHer2
Other,patientsWithHer-2PositiveExpression
Other,patientsWithHistoryOfBreastSurgery
Other,patientsWithHumanEpidermalGrowthFactorReceptor2
Other,patientsWithLocoregionalInSouthernPortuguese
Other,patientsWithMAmongThem
Other,patientsWithMeasurementErrors
Other,patientsWithMetastaticBreastCancer
Other,patientsWithNeoplasticDisease
Other,patientsWithReducedBaselineLvef
Other,paTreatment
Other,pattern
Other,patterns
Mechanism,patternsOfAssociationResults
Susceptibility,pb-ctMode
Gene,PCDH10
Other,pcdh10GenePromoterMethylationIdentifiedInDuctalCarcinoma
Disease,PCOS
Other,pcosGroups
Other,pCR
Other,pcrResults
Other,pcrThanWomenWithHr-positiveTumors
Other,pD1542yMissenseMutation
Mechanism,pdgfs/pdgfrsAxis
Hazard,peakInRecurrenceRisk
Other,Pearson
Other,pearson'sR
Other,penalizedLogisticRegression
Other,percecnt
Other,percecntConfidenceIntervals
Other,percecntRelapsedTissues
Other,percent
Care,perceptionOfQualityOfCareProvidedByCancerCareNetworkForEarlyDetectionOfBreastCancer
Exposure,performance
Exposure,performanceEvaluation
Other,performed
Other,performedFromInceptionToJanuary312018
Other,performedInFemaleParticipantsWithBreastCancerFromJune2015ToDecember2017
Other,period
Quantification,periodOfObservation
Other,periods
Other,peripheralBlood
Other,peripheralBloodSamples
Other,personalDecision-making
Other,personalGoals
Other,personalGoal-setting
Other,personalizedFollow-upSchemes
Other,perturbation
Other,PFS
Other,pH
Parameters,pharmacokineticParameters
Phenotype,phenotypeExpression
Other,phForHer2AgainstHer2-overexpressedBreastCancer
Phosphorylation,phosphorylation
Phosphorylation,phosphorylationOfAkt
Resistance,physicalActivity
Resistance,physicalActivityInPatientsWithMetastaticBreastCancer
Image,physicallyActive
Other,physician
Other,PI3K/AKT/mTOR
Other,pi3k/aktSignaling
Other,picture
Other,place
Other,planning
Other,plasmaLevels
Other,platform
Other,pLessthan
Other,pleuralDiseaseProgression
Disease,pleuralMetastasis
Other,pleurodesis
Other,pleurodesisForMalignantPleuralEffusion
Other,PM
Strategy,policyActions
Disease,polycysticOvarySyndrome
Other,pool
Other,poor
Other,poorAdhesion
Hazard,poorerOutcome
Other,poorerPrognosis
Other,poorerPrognosisInWomenWithBreastCancer
Other,poorPrognosis
Other,popular
Other,population
Other,population-basedStudies
Other,Porto
Other,portugueseInstitute
Other,portugueseWomen
Other,positive
Other,positiveChanges
Susceptibility,positiveChangesInTheirHealthBehaviours
Other,positivelyAssociated
Other,positivelyCorrelated
Regulatory,positiveRegulatoryFeedbackLoopForFxyd3Amplification
Other,positiveSln
Other,positiveTreatment
Other,possibility
Other,possibleCorrelationsWithClinicalStatusIncludingAge
Other,postAssessment
Other,posteriorFossaOfBrain
Other,postmenopausalPatient
Other,postmenopausalwomen
Other,postmenopausalWomenWithDevelopmentOfBreastCancer
Other,post-NAC
Other,post-nacBpeLevels
Other,postOperativeAssessment
Other,postoperativeComplications
Other,postponementVisiting
Other,potential
Resistance,potentialApplicationForDiagnosisOfCancerInFuture
Other,potentialBiomarkerForCancerDiagnosisThanMrnaBiomarkers
Exposure,potentialImpact
Exposure,potentialImpactOnFertilityAfterTreatment
Other,potentialImportanceAsModelsForHumanBreastCancer
Mechanism,potentialMechanism
Mechanism,potentialMechanismForFoxc1-inducedMetastasis
Other,potentialOfAionAsEffectiveMultimodalContrastAgentForBreastCancerDiagnosis
Other,potentialTarget
Other,potentialTherapeuticTarget
Strategy,potentialTreatmentStrategy
Strategy,potentialTreatmentStrategyForEndocrine-resistantBreastCancers
Gene,PR
Radiotherapy,practicalImplicationsOfOngoingChemotherapy
Other,practitionerDecisionmaking
Other,practitionersKnowledgeable
Other,pre
Other,preciseToolForTargetedTreatmentOfCancerIncluding
Other,precision
Other,preclinicallyTams
Other,preclinicalModels
Other,preclinicalPhase
Other,pre-diagnosticObesity
Other,prediction
Other,predictors
Other,predominant
Other,pregnancy
Other,pregnancyFrom1959To1966
Other,pregnancyOutcomes
Other,preliminaryGroupOfCtibl
Other,premenopausalPatients
Other,preoperativeAssessment
Other,pre-operativeAssessment
Other,preoperativeCytologicalDiagnosisOfBreastCancerMetastasesInRegionalLymphNodesIn84Patients
Other,preoperativeDiagnosis
Other,preoperativeUnderstanding
Other,presence
Other,present
Presentations,presentations
Other,presented
Survival,presentedWorkForFeatureExtraction
Other,preservationOfBiomarkerExpressionInOldFfpeTumour
Disease,pretermBirth
Other,prevalenceOfobesityOf277Percecnt
Other,prevention
Other,preventionOfDiagnosedBreastCancerInEstrogen-aloneArmOfWhi
Other,previousCervicalCancerScreening
Other,previousStudies
Care,primaryCareProvider
Other,primaryPurposeOfPeriodicMammogramsInScreeningProgramsIs
Disease,primaryTumor
Other,primaryTumours
Other,priorMedicalHistory
Susceptibility,proactiveManagementOfPsychologicalHealth
Other,probablyTranscriptionalActivation
Other,probe
Other,Probes
Other,problem
Other,procedure
Other,processes
Other,processing
Other,product
Other,profile
Other,prognosesOfYoungMenWithBreastCancer
Other,prognosis
Township,prognosisOfPatientsWithMaleBreastCancerInShanxiProvinceOfChinaFrom2007To2016
Other,prognostic
Other,prognosticFactorIndependentOfOtherClinicalVariables
Other,prognosticMeritOfNek6ExpressionInBreastCancer
Other,prognosticSignificanceOfNeutrophil-to-lymphocyteRatioInPatientsWithBreastCancer
Other,prognosticSignificanceOfNlrInEarlyStage
Other,prognosticStagingSystems
Other,prognosticValue
Other,program
Other,progressionDisease
Survival,progression-freeSurvival
Other,progressionOfTumorInvasionInBreastCarcinoma
Other,prohibitivelyExpensive
Other,proliferation
Other,proliferationOfCells
Other,proliferationOfMcf-7Cells
Other,promising
Short-term,promisingShort-termStrategiesPriorToTreatmentAdministration
Other,promisingSupplements
Other,promisingTherapeuticTargetForBreastCancer
Other,promoterMethylationInCertainTypesOfHumanTumors
Other,promoterMethylationStatus
Other,propagation-basedPhase-contrast
Other,propensityScoreMatchingAnalysis
Other,properAccessToDiagnosis
Other,properImaging
Other,properties
Other,proportion
Other,proposed
Other,proposedAlgorithm
Other,proposedCovariance-basedSpdMatrices
Other,proposedForBreastTumorGrading
Other,proposedMethod
Other,prospectivelyFollowedFor3YearsSinceDiagnosis
Other,prospectiveNestedCase-controlStudy
Other,prospectiveStudies
Other,protected
Other,protective
Other,protectiveFactor
Other,protectiveFactors
Other,protectiveRoleOfRs5743810
Other,proteinExpression
Other,proteinExpressionOfNf-krab-p65
Other,proteinKinase
Other,proteinS-100
Gene,Protocadherin-10
Protocols,protocols
Other,psychologicalAspects
Other,public
Strategy,publicHealthCareSystem
Susceptibility,publicHealthChallenge
Other,pureDcis
Other,pureDcisInClinicopathologicCharacteristics
Other,purpose
Other,q12X
Other,quadrantectomy
Other,qualitativeApproach
Other,quality
Symptom,qualityEvidence
Other,qualityOfLife
Other,quality-of-lifeFactorsForSurvivorsIncludingSexualDysfunction
Other,qualityOfLifeOfPatients'Spouses
Quantification,quantification
Parameters,quantitativeParameters
Other,quantitativeRealTimeFluorescencePolymeraseChainReaction
Other,queried
Exposure,questionnaireBasedOnAnderson'SdelayModel
Other,R
Other,r
Other,racialDisparity
Survival,radiation
Other,radiationTherapy
Other,radioisotope
Other,radiologicalSignsOfMalignancy
Other,radiomics
Other,radiomicsScore
Other,Radiotherapy
Radiotherapy,radiotherapy
Exposure,randomEffectsModel
Other,random-samplingMethod
Other,ranging
Technique,rangingFromDiagnosisPhaseToControlOfDisease
Gene,RANKL
Other,rapidBreast-cancer-tissueDiagnosis
Other,rare
Presentations,rareClinicalPresentations
Presentations,rarePresentations
Other,rareTumor
Other,rate
Other,rates
Other,ratio
Other,rationaleForTamsAsTherapeuticTargetInBreastCancer
Disease,RDD
Other,reality
Other,realNeedOfSurgicalTreatment
Other,real-time
Other,real-worldSetting
Other,receivedWithoutSurfaceModification
Other,receiverOperatingCharacteristic
Other,receiverOperatingCharacteristicCurves
Other,recentDanishCohortStudy
Other,recentDevelopments
Other,recentEpigenomeStudies
Other,recentlyDiagnosedBreastCancer
Other,recentlyHaveUsedAsBiomarkers
Other,recentStudies
Other,recentYears
Other,receptorActivator
Other,recognized
Other,recognizedAsCtcIn1Of15HealthyBloodSamples
Other,recognizingMethylationStatus
Other,recommendations
Other,recommended
Other,recurrence
Other,recurrence-free-survival
Other,Recurrences
Other,recurrentWords
Other,reducedBaselineCardiacFunction
Other,reducedBaselineLvef
Other,reference
Other,referenceForClinicians
Other,referral
Other,Referrals
Other,regression
Exposure,regressionModel
Other,regressionModels
Other,regulated
Other,regulationOfNras
Other,relapse
Other,relapseRates
Other,related
Other,relatedResearchDataOfDiagnosisOfInoperableLocallyAdvancedBreastCancer
Other,relatedTranscriptionFactorSox9
Other,relation
Other,relationship
Other,relationshipBetweenNlr
Other,relationshipBetweenStromalExpressionOfPodoplaninInInvasiveBreastCarcinoma
Advantage,relativelyGoodPrognosisWith5YearOverallSurvivalOf88Percecnt
Other,relativeThose
Other,relativeThoseOfPostmenopausalPatients
Survival,releaseFromSerumStarvationInMcf-7Cells
Survival,releaseProfile
Other,relevant
Other,remarkableImprovements
Other,repair
Other,replaced
Other,report
Other,reported
Assays,reporterAssays
Exposure,reportOnPerformanceOfBayesClassifiersLikeTreeAugmentedNaiveBayes
Other,represented
Other,required
Other,research
Other,Researchers
Other,researchers
Susceptibility,researchLight
Other,Residents
Resistance,resistance
Resistance,resistanceToMultipleTypesOfTreatmentInBreastCancerModels
Other,resistant
Other,resonanceImaging
Other,resources
Other,respectivelyFound
Other,respondents
Signature,response
Signature,responseRate
Other,responsible
Other,responsibleMechanisms
Other,restoration
Hazard,result
Hazard,resultCompatibleWithMetastasisToOrbit
Hazard,resultOfPreviousOrbitalBiopsy
Other,Results
Other,results
Other,resultsDiagnosed
Other,resultsOfStudy
Other,Resurgery
Other,retrieved
Other,retrospective
Other,retrospectiveObservationalStudyOf264Her2-positiveAdvancedBreastCancer
Other,retrospectiveStudies
Other,retrospectiveStudyOfWomenTreatedWithTrastuzumabForHumanEpidermalGrowthFactorReceptor2BreastCancerAtMayoClinicBetweenJanuary12000
Other,revealed
Image,reverseActiveLearningForClassificationOfHealthyBreastTissue
Other,reverseTranscriptionQuantitativePolymeraseChainReaction
Other,reverseTranscription-quantitativePolymeraseChainReaction
Other,review
Strategy,revisionsOfAjccBreastCancerStagingSystem
Other,ribonucleotideReductaseM2
Other,richSpectralFeaturesOfPhenyboronicAcid-basedNanoprobe
Biopsy,rightMastectomyWithSentinelLymphNodeBiopsy
Hazard,Risk
Hazard,risk
Other,risk/benefitOfDifferentTreatmentModalities
Hazard,riskFactor
Hazard,riskFactorForLung/bronchusCancer
Hazard,riskFactors
Hazard,riskFactorsOfLvi
Hazard,riskFactorsOfLviByMultivariateAnalysis
Hazard,riskForRecurrence
Hazard,riskOfBreastCancerInAdulthood
Hazard,riskOfDeath
Hazard,riskOfDevelopmentOfGliomas
Hazard,RiskProtection
Other,risks
Other,risksOfLate-stageDiagnosis
Hazard,riskStratification
Strategy,risk-stratifiedScreeningStrategy
Other,rituximab
Other,RL
Other,rnaKnockdown
Other,rnaOligonucleotides
RNAs,RNAs
Other,rnaSequenceAnalysis
Other,robust
Other,robustSynthesisMethods
Other,robustTechnology
Other,role
Autoantibodies,roleOfAutoantibodiesInEarlyCancerDiagnosis
Other,roleOfEstrogens
Phenotype,roleOfImage-basedTextureFeaturesAsNoninvasivePrognosticBiomarkers
Mechanism,roleOfPdgf-b/pdgfr-betaAxisInRareTypesOfBreastCancers
Other,roleOfPrimaryCaregiver
Other,roleOfSupportOfferedByVirtualCommunitiesToBreastCancerPatients
Other,rolePlayedByPdgfFamilyMembersInNormalDevelopmentOfBreastTissueDespiteItsPotentPro-lymphangiogenicEffects
Other,roles
Other,RON
Other,ronInternalization
Other,ronReceptorTyrosineKinase
Other,RRM2
Other,rrm2Expression
Mutation,rs5743810
Other,rs5743810ProAllele
Care,rural-basedTertiaryCancerCareCenter
Other,ruralCancerHospital
Other,ruralSetting
Other,S
Other,S+RT
Other,safety
Other,sameRangeAsCasesWithoutWavelength-dependentMeasurementErrors
Other,sample
Other,samples
Other,satisfied
Other,saudiArabianWomen
Other,scalable
Care,scalableIntervention
Other,scan
Other,scffbxo22-mediatedKdm4bDegradation
Other,scope
Other,score
Other,screened
Other,Screening
Other,screening
Other,screeningBehavior
Other,screeningPrograms
Strategy,screeningStrategy
Other,screeningTools
Other,scrutinised
Other,scrutinized
Other,SD-CNN
Other,SE
Other,search
Other,secondary
Other,secondaryConfirmationOfSignalAccumulationUsingNearInfraredFluorescentImaging
Other,secondaryLymphedema
Other,secondDecadeAfterDiagnosis
Other,secondLargestHmo
Risk,secondLeadingCause
Other,secondSurgery
Other,secondTumor
Other,secretion
Other,secretionOfTumorNecrosisFactor
Other,seen
Other,segmentationAlgorithm
Other,selectedPatients
Other,selectedStandardTreatments
Vivo,selectiveAccumulationOfFluorescentOsteopontinInVitroAndInVivo
Other,selectiveBinding
Other,sensitive
Other,sensitiveNano-genosensor
Other,sensitivity
Other,sensitivityOf786PercecntRespectively
Other,sensor
Other,sentinelLymphNode
Biopsy,sentinelLymphNodeBiopsy
Biopsy,sentinelNodeBiopsy
Other,sentinelNodes
Other,separateClassificationModels
Other,sequencing
Other,serious
Other,serumSamplesFromCancerPatients
Other,seValues
Other,sevenWomen
Other,severalIntelligentTechniques
Other,severalObjectives
Other,severalOtherGenes
Other,severalPatients
Disease,sexualDysfunction
Other,sexualStigmatizationOfM
Other,shallowCnn
Other,shallow-CNN
Township,shanxiProvinceOfChina
Other,shaped
Other,shapes
SNVs,sharedSnvs
Other,she
Other,She
Other,shorterIntervalsBetweenD
Radiotherapy,shorterRadiotherapyRegimens
Strategy,short-termStrategy
Other,shouldCo-managed
Other,shouldCo-managedByCardiologist
Other,shouldElaborated
Other,shouldKept
Resistance,shouldOvercomeBeforeClinicalApplication
Other,shouldPerformed
Hazard,shouldPerformedInAtRisk
Other,shouldProceede
Other,shouldProcessed
Other,shouldStaged
Other,show
Other,shown
Other,sialicAcidExpression
Other,sideEffects
Other,sideEffectsOfBreastCancerTherapiesIncludingHotFlushes
Other,signalAmplificationStrategies
Other,signalIntensity
Signature,signature
Other,signatures
Other,significance
Other,significanceLevel
Other,significanceOfTime-trends
Other,significant
Other,significantAdvances
Mechanism,significantAssociationBetweenLevelsOfNek6
Mechanism,significantAssociationBetweenRs5743810AllelicFrequency
Other,significantCausativeGenes
Other,significantChallenge
Other,significantDifference
Hazard,significantHigherRisk
Other,significantIncrease
Other,significantlyAssociated
Other,significantlyCorrelated
Survival,significantlyCorrelatedWithOverallSurvival
Other,significantlyCorrelatedWithTumorSize
Other,significantlyDecreased
Other,significantlyHigher
Other,significantlyHigherBaselineBpeLevelsThanPostmenopausalWomen
Other,significantlyHigherPcrRatesThanPatientsWithLuminalTypes
Other,significantlyProlongedMedianPfs
Other,significantlyReduced
Other,significantlyUp-regulated
Other,significantlyYounger
Other,significantlyYoungerAge
Other,similar
Parameters,similarExperimentalParameters
Other,similarPfs
Other,similarSeriousAdverseEvents
Other,similarTendencyRelatedWithPrognosticFactors
Other,similarTowaveletFilter
Other,simulatedBreastCancer
Other,simulatedInnerBreastTissue
Other,single-cellWhole-exomeSequencing
Other,singleMetastaticSite
Variants,single-nucleotideVariants
Sites,sites
Other,site-specificBindingLeadingToImprovedCancerTreatmentWithMinimalRisksToNormalCells
Other,sixCirculatingMirnas
Sites,sixGlycosylationSites
Other,sixteenRegionsOfKazakhstan
Other,sleepDisturbances
Biopsy,slnBiopsy
Other,slnMetastasis
Other,small
Other,smallerMyeloperoxidase
Other,smallMoleculeInhibitors
Other,smallPopulation
Other,smallProportion
SNPs,SNPs
SNVs,SNVs
Other,soFarHasMainlyAssociatedWithMutationsInBrca1
Other,solicitations
Other,solidTumors
Other,solubleSt-2Level
Other,sometimesMistaken
Other,southernPortuguese
Gene,SOX9
Other,sox9NucleusEntry
Other,SP
Other,sparseCoding
Other,sparseCombinationOfRiemannianDictionaryAtoms
Other,sParticipants
Other,SpCM
Other,spdMatrices
Other,specialType
Susceptibility,specificallyPlacedOnInflammatoryBreastCancerWithSkinInvolvementOnCutaneousMetastasesToBreastFromBreastCancer
Other,specificCancerCell-relatedComponents
Other,specificCircumstances
Other,specificEralpha-targetedProbe
Other,specificFoodRecommendations
Other,specificGroups
Subtype,specificSubtype
Other,specimen
Other,spectrum
Other,speed
Other,spindleCells
Other,splenicLymphocytes
Other,spouse
Other,Spouses
Other,spouses
Other,SRC
Other,ssdnaAptamerMf3
Other,st-2Level
Other,stable
Mechanism,stableBodyWeight
Other,stableDrug-carrierBinding
Other,stage
Other,stageI/iiaCases
Other,stageIi
Other,staging
Other,stagingSystems
Other,staining
Other,standard
Other,standardBiomarkerTestingByImmunohistochemistry
Other,standardizedDataCollection
Other,standardMethod
Other,standardMethodForEvaluationOfProposedPrognosticTumourMarkers
Care,standardOfCareAsFirst-lineTreatmentOfPatientsWithHer2-positiveAEvenInReal-worldSetting
Care,standardOfCareForBreastCancer
Gene,STAT1
Other,stat1RecruitmentToEralphaPromoterRegion
Other,state-of-the-artAlgorithms
Mechanism,statisticalAssociation
Other,statisticalClassifiers
Other,statisticallyCorrelated
Other,statisticallySignificantValuesAt4Cells/7MlBlood
Other,status
Other,Stem-likeCells
Other,Steps
Biopsy,stereotacticWire-guidedBiopsy
Other,stigmatization
Other,stillDifficult
Other,stillObscure
Susceptibility,stillSeriousHealthProblemIn21stCenturySubjectToManyResearch
Strategy,strategy
Other,stratification
Other,stratifyingForAge
Other,stromalExpression
Other,strong
Hazard,strongAssociationBetweenRs5743810AgainstRiskInSaudiArabianWomen
Other,strongContrast
Other,strongContrastWithImagingModalities
Other,strongIndependentPrognosticFactor
Other,stronglyPositive
Phenotype,structureChanges
STs,STs
STs,stsOfDeath/relapse
Other,studies
Other,study
Other,study'sObjectives
Other,subgroupVariables
Hazard,subjectiveRisk
Other,subsequentCancerCounselingOfFemaleSurvivors
Other,subsequentLung/bronchusMalignancies
Other,subsequentlyAssessed
Other,subsequentMalignancies
Other,subsequentMalignanciesForLung/bronchusCancerWith13PercecntSurvivorsSufferedFromSubsequentMalignancies
Other,subsequentPrimaries
Other,subsequentRadiomics
Other,subset
Other,substantialDiscordancesBetweenPrimaryTumors
Other,substantialImprovements
Subtype,subtype
Other,subtyped
Other,subtypes
Other,subtype-specificPrognosticSignatures
Signature,subtype-specificSignature
Other,successfulFunctionalizationOfNanocompositeOfSpecificSequenceOfAminatedComplementaryOligonucleotideOfMirna-21
Quantification,successfulQuantification
Quantification,successfulQuantificationOfCa15-3InSerumSamplesFromCancerPatients
Other,successOfSymmetricPositiveDefiniteMatrices
Other,suchLowIncidence
Other,suchStandardization
Other,suchSymptoms
Other,sufferingFromWoman'sDisease
Other,suggested
Other,sulass
Other,summary
Hazard,summaryHazardRatios
Other,supplements
Other,support
Other,supportVectorMachine
Cytology,surfaceMorphology
Other,surgery
Other,surgicalExcision
Survival,surgicalExcisionWithRadiation
Other,surgicalImplantationReconstruction
Other,surgicalOptionsIncludingPreservationOfNippleAreolaComplex
Hazard,surgicalOutcome
Other,surgicalOutcomes
Other,surveillanceData
Other,surveillancePopulation-basedData
Other,Survival
Survival,survival
Other,survivalData
Survival,survivalDifferences
Other,survivalDistributions
Survival,survivalPrediction
Survival,survivalRate
Survival,survivalRates
Survival,survivalThanAdjuvantTherapy
Survival,survivalVariance
Other,suspected
Other,sustainedStableDisease
Other,suutaneousBreastTumor
Other,suutaneousEcchymosis
Other,suutaneousLymphaticChannels
Other,suutaneousLymphaticChannelsInReal-time
Other,SUVmax
Other,SVM
Other,SVM-BRC
Other,switch
Other,switched
Symptom,symptom
Other,symptomaticHeartFailure
Other,symptomaticWomen
Symptom,symptomBurden
Other,symptoms
Survival,synchrotronRadiation
Syndrome,syndrome
Other,syndromes
Other,synonymous
Other,synthesisMethods
Other,synthesized
Strategy,system
Radiotherapy,systemicChemotherapy
Other,T2
TAAs,TAAs
Other,tackled
Other,taiwanLongitudinalHealthInsuranceDatabase2005
Other,TAM
Chemical,tamoxifen
Resistance,tamoxifenResistance
Other,tamoxifen-resistanceInErCancerCells
Other,TAMs
Other,tangshanPeople
Other,tanUsage
Other,target
Other,targetedTherapies
Other,Targeting
Other,targetingFxyd3-mediatedPathway
Other,targetRelationshipBetweenDscam-as1
Targets,targets
Other,TBR
Other,team
Technique,technique
Other,techniques
Other,tendency
Other,tenfoldCross-validationMatthew
Other,termsOfClassification
Other,termsOfKyotoEncyclopediaOfGenes
Mechanism,termsOfMechanism
Susceptibility,tertiarySexualHealthCenters
Other,tested
Other,testing
Other,testingDatasetsCollectedFrom48Patients
Other,tests
Other,textureAnalysis
Phenotype,textureFeatures
Other,thanCapecitabineGroup
Other,thanDcis
Other,that
Other,thatInMabaGroup
Other,thatInNon-pcrGroup
Other,thatOfMir-511
Other,thatOfOtherCountries
Other,the
Other,their
Other,theirAbility
Other,theirAbilityOfPrognosisPredictionInTheirOriginallyTargetedPopulationsOfBreastCancer
Resistance,theirApplication
Other,theirBeliefsRegardingCancerCausation
Care,theirCare
Mechanism,theirContraceptivePreferences
Other,theirExperiencesLivingWithSister
Susceptibility,theirHealthBehaviours
Long-term,theirLong-termSurvival
Other,theirOriginallyTargetedPopulationsOfBreastCancer
Other,theirOwnParticularity
Other,theirParaffin-embeddedTissues
Other,theirParticularity
Other,theirPotentialClinicalImplicationsOnBreastCancer
Exposure,theirQuestionableImpactOnMortalityOnIncidenceOfAdvancedTumors
Radiotherapy,theirRelatedMarkersAtDifferentPointsOfChemotherapyRegimensInMetastaticBreastCancer
Hazard,theirRisk
Survival,theirSurvival
Other,theirTissues
Other,them
Other,thematicAnalysis
Other,themselves
Other,themVeryDifficult
Other,thenAdded
Other,thenClassifiedBySupportVectorMachines
Township,thenLinkedToTownshipFemaleBreastCancerIncidenceRateIn2000s
Other,thenPresented
Other,theory
Care,theory-basedIntervention
Other,thepresence
Other,therapeuticAdvantagesParticularlyInCaseOfPremenopausalBreastCancers
Other,therapeuticEffectsInBreastCancer
Other,therapeuticSequencing
Other,therapeuticTarget
Other,therapeuticTargetForPotentialTreatment
Other,Therapies
Other,therapies
Other,therapy
Other,therapy-relatedConditionsDuringBreastCancerSurvivorship
Other,therebyFrequentlyNeglected
Other,thereforeAdministered
Other,thereforeApplied
Other,thereforeCentralTarget
Other,thereforeCriticalSignificance
Susceptibility,thereforeHasAppliedToEarlyIdentification
Other,thereforeRequired
Other,theResulting
Other,They
Other,they
Cell,theyCanImpactOnQualityOfLifePresent
Other,third
Other,thirdInTermsOfSpecificMortality
Other,third-lineTreatmentForAdvancedTriple-negativeBreastCancerthisRetrospectiveStudy
Other,This
Other,this
Other,those
Other,thoseWithHr-positiveTumors
Other,thoughtfulMultidisciplinaryPlanning
Other,threeCtcsIsolatedFromOnePatient
Other,threeDifferentClusters
Other,threeDifferentUsMachines
Signature,three-lncrnaSignature
Survival,threeOverallSurvival
Other,threeYearsBeforeAge64Years
Survival,three-yearSurvivalRates
Other,thriceHigher
Other,throughOptimizationTestsChosenAsOptimalConditions
Other,thusAimed
Other,thusCritical
Susceptibility,thusInRecentYearsDemand
Other,thusMeaningful
Other,thusPotentialTherapeuticTarget
Resistance,thusWouldCrucialForApplicationOfPreventiveStrategies
Other,tightDoctor-patientCollaboration
Other,time
Other,timeInMostCountries
Other,timeIntervalsFromFirstDetectionToDiagnosis
Other,timeOfTheirAppointmentwithDoctor
Other,times
Other,time-varyingPost-diagnosisLow-doseAspirinUse
Radiotherapy,timingOfChemotherapyForBreastCancersWithDifferentMolecularBackgrounds
Other,tissue
Biopsy,tissueBiopsy
Other,tissueDiagnosis
Other,tissueMicroarray
Other,tissues
Other,tissueStorageTime
Other,tnmStage
Other,toEndDevelopedWithDrugToAntibodyRatioOf329
Other,tolerabilitytheApatinib
Other,tomography
Other,tool
Other,tools
Other,total
Other,totalGroup
Other,totalHemoglobinConcentration
Other,totalOf121Patients
Other,towaveletFilter
Township,township
Gene,TP53
Other,traditionalPredictors
Other,training
Care,transcriptionFactorForkheadBoxC1
Other,Transcripts
Other,transferLearning
Other,transport
Other,trastuzumab
Other,trastuzumab/pertuzumab/taxane
Other,trastuzumabInitiation
Other,trastuzumabTherapy
Other,trastuzumabTherapyForBreastCancer
Neuromas,traumaticBreastNeuromas
Other,traumaticNeuroma
Other,treat
Other,treated
Other,treatedWithCapecitabineMonotherapyAsThird-lineTherapy
Other,treatedWithIntraperitonealInjectionFor30Days
Other,treatingMedicalTeam
Other,treatment
Other,treatmentMoreAccessibleToBreastCancerPatients
Other,treatmentOfBreastCancer
Hazard,treatmentOutcomePrediction
Other,treatmentProcesses
Protocols,treatmentProtocols
Other,treatmentRegimens
Other,treatments
Other,treatmentStrategies
Strategy,treatmentStrategy
Other,treatmentTherapy
Other,trend
Other,tripleAssessmentFollowed
Disease,triple-negativeBreastCancer
Disease,triple-negativeBreastCancers
Subtype,triple-negativeSubtypeMda-mb-231Cells
Other,troponins
Other,TRPV1
Disease,tumor
Other,tumor-1
Other,tumor-associatedMacrophages
Other,tumor-bearingMiceOfMcf-7BreastCancerCells
Other,tumorBurden
Other,tumorCells
Other,tumorEasily
Other,tumorGrowth
Other,tumorGrowthInExperimentalModels
Other,tumorigenesisOfBreastCancer
Other,tumorigenesisOfCells
Other,tumorImaging
Other,tumorNecrosisFactor
Other,tumorNeoangiogenesisSimilarToBreastMagneticResonanceImaging
Tumor,tumorNippleDistance
Disease,tumors
Other,tumorSize
Advantage,tumorSizethePositivity
Other,tumorSuppressorFunction
Other,tumorSuppressorFunctionOfP53InPathogenesisOfBreastCancer
Other,tumorSuppressorGene
Other,tumor-to-backgroundRatio
Other,tumorUptake
Disease,tumour
Disease,tumours
Disease,Tumours
Other,tumourSpread
Other,twenty-twoPatients
Other,twentyUniqueEsr1Mutations
Other,twoCases
Other,twoCasesOfMimicsOfBoneMetastasis
Other,twoChlorambucilPlatinum
Other,twoGroups
Other,twoImagingIndexes
Other,twoLargeBreastCancerDatabases
Other,twoScales
Other,two-thirdsOfBreastCancerCases
Other,twoUncommonCasesOfDelayedBreastCancerRelapses
Other,twoYears
Other,two-yearStudy
Other,type
Other,type160Patients
Other,typeOfCollisionTumor
Other,typical
Other,typicalHormone-dependentTumor
Other,typicalWoman
Other,typicalWoman'sDisease
Other,ultrasound
Other,ultrasound-guidedDiffuseOpticalTomography
Other,unbiasedRnaSequenceAnalysis
Other,unclear
Other,uncommon
Correlation,uncouplingOfInverseCorrelationBetweenBmi
Other,uncover
Other,undergoing
Other,undergone
Other,understand
Other,understanding
Other,understandingOfEmergingConceptsOfTumorBiology
Other,understood
Other,understudied
Other,understudiedPattern
Other,underutilized
Other,undiagnosed
Other,undifferentiatedNeoplasticCells
Other,unilateralBreastCancer-relatedLymphedema
Other,uniqueEsr1Mutations
Other,uniqueProperties
Other,univariableLogisticRegressionModels
Other,Univariate
Other,unknown
Other,unmetPsychosocialNeeds
Other,unnecessaryFollow-upVisitsForWomenWithVeryLowRisks
Other,unusual
Other,unusualCaseOfPtosis
Other,upregulated
Other,up-regulated
Other,uptake
Other,urgent
Other,urgentClinicalProblem
Cytology,urgentCytology
Other,urgentlyAdvanceImplementation
Other,urgentlyDeveloped
Other,urgentlyNeeded
Other,us
Other,Use
Other,use
Other,used
Other,useful
Other,usefulness
Other,users
Other,usExaminations
Other,Using
Other,usStandardization
Care,usualCare
Other,usuallyAssociated
Other,utility
Other,Utilization
Other,utilization
Other,utilized
Other,Validation
Other,value
Other,values
Gene,VAP-1
Other,vap-1Expression
Other,vap-1ImmunohistochemicalStaining
Other,vap-1NegativeStaining
Other,vap-1Staining
Other,vap-1StainingResults
Other,variableMolecularMechanismsOfCarcinogenesis
Other,variables
Susceptibility,variablesPredictiveOfNippleAreolaComplexInvolvementInPatients
Variants,variants
Other,variousArtifactsIntroducedDuringSlidePreparation
Cell,variousCellularProcessesCellCycleRegulation
Other,variousEnvironments
Other,variousImportantFunctions
Toxicity,variousLimitationsIncludingToxicity
Other,variousMethods
Other,variousNon-pharmacologicalAdjuvantTherapies
Mechanism,variousOtherCancerInHumanBody
Other,variousRadiologicalChangesLeadingToDiagnosticChallenges
Gene,vascularAdhesionProtein-1
Gene,VEGF-D
Other,veryComplexDisease
Other,veryHeterogeneousDisease
Other,veryRareCaseOfTraumaticBreastNeuroma
Other,veryRareClinicalEntityWithOnlyFewCasesHavingReportedToDate
Other,v-gCalciumChannelBindingAntibodies
Other,virtualReality
Other,virtualRecombinedImagesFromLeImages
Other,visits
Other,visualizedTheranosticsOfTumors
Other,vital
Other,vitalRole
Other,vitalRoles
Other,volume
Other,volumes
Vulnerability,vulnerability
Other,water
Other,wavelengthConsistencyIndex
Other,We
Other,we
Other,weak
Cell,weakToStrongReactivityToOtherCellLines
Other,weight
Other,well-established
Other,WES
Other,westernBlot
Other,westernBlotAnalyses
Other,westernBlotAnalysis
Other,westernizedCountries
Image,whenActiveUse
Other,whenGiven
Susceptibility,whenIntegratedWithinCountry/region'sHealthPlan
Other,whenonlyAnalyzed
Other,whenSuspected
Other,whereDeveloped
Other,whereFacilitatedBySurfaceModificationOfNps
Other,WHI
Quantification,whole-tumorSamplingOfDiseaseBurden
Care,widelyAcceptedAsStandardOfCareFollowingBreastConservation
Other,widelyExpressed
Other,widelyUtilized
Advantage,widespreadInterest
Other,willDifferent
Subtype,willDifferentRegardingSubtypeAtDiagnosis
Advantage,willLeadToMortalityReductionsWithoutUsualScreeningHarms
Other,willTested
Other,willTestedThroughEuropeanMyPersonalBreastScreening
Other,willUsed
Other,willUsedAsReferences
Other,Wilm
Other,withandControllingForTreatmentDelays
Other,withBetterDrugDeliveryPotentialOfNon-sphericalShapesHaveRecentlyInvestigated
Other,withDevelopmentOfHigh-throughputSequencingHaveDiscoveredInTumorousTissues
Species,woman
Species,women
Species,Women
Other,womenInWorld
Other,womenOfReproductiveAge
Other,women'sCancerAccounting
Other,women'sPersonalGoals
Other,womenWithBreastCancer
Other,womenWithG
Other,womenWithMore70PercecntOfPatientsTreatedWithHormonalTherapy
Other,womenWorldwide
Other,wordCloud
Other,workflowConsistingOfImmunoaffinityPurification
Other,world
Other,worldwide
Other,worldwideHighestAge-standardizedBreastCancerIncidence
Hazard,worseOutcome
Other,xenograftMice
Other,x-rayMammography
Other,year
Other,yearRfsrate
Other,years
Other,yoga
Other,young
Other,youngAge
Other,younger
Other,youngerAge
Other,youngerBreastCancerSurvivors
Other,youngMalePatients
Other,youngMen
Other,youngMexicanWomen
Other,youngWomen
Other,youngWomenWithInvasiveLobularCarcinoma
Other,YS
Exposure,zebrafishTumorModel
Other,zero-inflatedPoissonRegression
Other,Zt/g4-MMAE
Other,z-test
Other,=-25-diphenyltetrazoliumBromideAssay